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Abstract The age-related epithelial cancers of the breast,
colorectum and prostate are the most prevalent and are in-
creasing in our aging populations. Epithelial cells turnover
rapidly and mutations naturally accumulate throughout life.
Most epithelial cancers arise from this normal mutation rate.
All elderly individuals will harbour many cells with the req-
uisite mutations and most will develop occult neoplastic le-
sions. Although essential for initiation, these mutations are not
sufficient for the progression of cancer to a life-threatening
disease. This progression appears to be dependent on context:
the tissue ecosystem within individuals and lifestyle expo-
sures across populations of individuals. Together, this implies
that the seeds may be plentiful but they only germinate in the
right soil. The incidence of these cancers is much lower in
Eastern countries but is increasing with Westernisation and
increases more acutely in migrants to the West. A Western
lifestyle is strongly associated with perturbed metabolism, as
evidenced by the epidemics of obesity and diabetes: this may
also provide the setting enabling the progression of epithelial
cancers. Epidemiology has indicated that metabolic bio-
markers are prospectively associated with cancer incidence
and prognosis. Furthermore, within cancer research, there has
been a rediscovery that a switch in cell metabolism is critical
for cancer progression but this is set within the metabolic
status of the host. The seed may only germinate if the soil is
fertile. This perspective brings together the different avenues
of investigation implicating the role that metabolismmay play
within the context of post-genomic concepts of cancer.
Keywords Metabolism . Breast cancer . Prostate cancer .
Colorectal cancer . Lifestyle
1 Introduction
In the developed world, malnutrition and infectious diseases
no longer restrict lifespan resulting in a shift in the demo-
graphics with increasing populations of elderly people and
increasing prevalence of age-associated disorders. Cancer is
one such age-associated disorder and is an ever increasing
challenge for Westernised societies. In the USA, cancer is the
number two killer with around 1.5 million new cases each
year and more than a half million deaths. It is also now the
main cause of premature death, having overtaken cardiovas-
cular disease as the major cause of mortality in all but those
over the age of 85 years [1]. For most people, a premature
death is of greater concern than death into the eighth or ninth
decade after a full life. In 1971, President Richard Nixon
famously declared war on cancer with the mission: ‘to find a
cure for cancer’. In the subsequent four decades, there have
been many major advances in our understanding of the
molecular pathology of cancer but these advances have been
slow to translate and to have major impact in the clinic. In the
USA, during the period 1951–2001, the death rates from
heart disease, cerebrovascular disease, pneumonia, and in-
fluenza were reduced by more than half but in contrast the
death rate from cancer remained unchanged [2].
For many decades, the favoured concept for why we get
cancer has been the somatic mutation theory, with cancer
being caused by an accumulation of gene mutations: either
from gain of function of oncogenes or from loss of function
of tumour suppressor genes or mutations in DNA-integrity
genes [3]. Research identifying and characterising these
cancer genes was so successful that the concept that these
gene mutations were the most important determinants of
cancer became the widely accepted dogma. This created
early hope that studies of oncogenes and tumour suppressor
genes would yield many new treatment targets resulting in
numerous, novel interventions that would revolutionise how
we manage clinical cancers. Although our knowledge and
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understanding has grown enormously over the last few de-
cades, much of that early hope has not been fulfilled. The
exploration of the cancer cell genome has led to dramatic
developments in the treatment of some cancers, such as
childhood leukemia, Hodgkin’s disease and testicular cancer.
In addition, the overall mortality from some of the common
cancers has been falling recently because of advances in
early detection and treatment. The statistics may also be
distorted because of the increasing detection of early indo-
lent cancers that would never progress to fatal disease lead-
ing to a false impression of increasing survival. Despite these
advances, for the most common epithelial cancers (lung,
breast, prostate and colorectal), the prognosis for patients
with metastatic disease has seen little improvement. The vast
majority of deaths due to cancer result from metastatic
disease that is resistant to current therapies [4]. There
has however been an accumulation of evidence from a
variety of fields that when integrated together may give
us a clearer view of these cancers and the clinical
challenges that they present.
2 Epithelial cancers have large numbers of mutations
but generally these are naturally acquired
Despite popular perception, cancers generally do not arise
from a mutation in a single gene or even from mutations in a
small number of genes. Elaborate mechanisms have evolved
to protect against gene mutations directly leading to lethal
cancers. It is now clear that by the time a tumour is clinically
apparent, it has accumulated a large number of mutations,
many of these are not within gene coding sequences (the
significance of which is yet to be understood) and there is
considerable variation in mutations between tumours even
those in the same tissue. Mutations contributing to cancer
pathophysiology are termed driver mutations whereas those
not currently known to contribute are termed passenger
mutations. It is thought that for most cancers the initiation
and progression is primarily due to a few common driver
mutations but there are also many additional plausible driver
mutations that occur at low frequency or are idiosyncratic to
an individual clone of cells. The malignant phenotype is a
result of the collaborative effect of these many mutations that
could number into their thousands for any particular tumour.
For breast and colorectal cancers, one study estimated that
there were around 100 mutations per cancer that were
nonsynonymous (affecting coding for protein sequence)
with as many as 20 suggested as driver mutations potentially
playing a role in carcinogenesis [5, 6].
Gene mutations occur generally because of errors during
DNA replication or from exposure to genotoxic agents. Cells
that are frequently replicating are at much higher risk and
although cell proliferation is most active during early
development and childhood, in general human cancer is a
disease of aging: presumed to be due to the requirement for
an accumulation of mutations. Errors in DNA replication
occur naturally at a rate of around 10−10 to 10−9 per nucleo-
tide per cell per division: this is not a failure in the biology
but indeed is central to evolution [7]. It now seems likely that
most cancers are initiated in cells because of this normal
mutation rate: studies that have measured the numbers of
mutations in common cancers have provided evidence con-
sistent with this natural rate. Mutations that contribute to
oncogenesis can occur in the germline and result in heredi-
tary predisposition to cancer or more often they occur in
single somatic cells that result in sporadic cancers. The vast
majority (around 98 %) of human cancers that present clin-
ically are sporadic, rather than inherited, and the majority of
these (around 90 %) are carcinomas that generally occur in
epithelial cells: these are cells that continuously divide to
replenish epithelial barriers; for example, the human colon is
a tissue with relatively high rates of epithelial cell division
and has approximately 1–1.5×107 crypts, each one
maintained by a small number of stem cells. In mice the
identification of a potential stem cell marker has enabled an
estimation of crypt stem cell division as around once per day
[8]. In humans, there is no such evidence but estimates of
crypt stem cell division are between once every 1–4 days.
Simple mathematics indicates that this should generate an
accumulation of mutations over a life-course such that by the
age of 70 years: a cell division rate of once per day would
yield around 2.6 mutations/100,000 bases and a cell division
rate of once per 4 days would yield 0.65 mutations/100,000
bases [9]. For colorectal cancers, actual measurements of the
prevalence of mutations in tumours have now been reported
as less than 1 mutation/100,000 bases [5, 10]. Combining
these strands of evidence indicates that the normal mutation
rate and the cell turnover rate are sufficient to generate cells
with a cancer genotype over a normal lifespan. An important
consideration is that these simple calculations are based on
average rates calculated for the average cell, but in any
individual human, a cancer is presumed to develop when
just one cell accumulates the critical number and combina-
tion of mutations. The risk of just one, out of more than 15
million, crypt stem cells reaching this threshold is consider-
ably greater than the risk for an average cell. The accumula-
tion of genetic mutations in a tumour generates a cancer
genome that varies from that of the somatic germline genome
by <1 base/100,000 bases: this is a relatively small difference
in comparison to the variance that occurs for the germline
genome between different individuals. There is also huge
variation in cancer genomes between patients even with
tumours in the same tissue [5, 6]; this undoubtedly is partly
due to the tumour genome variations developing from
germline genomes that themselves vary considerably
between individuals.
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That a cancer genome can be generated naturally from
normal cell division is also consistent with measures of the
accumulation of mutations in normal tissues from individ-
uals without cancer. A study of mutations in the oncogene
p53 in normal cancer-free adults found that there were
around 50 clones of cells with mutated p53 within every
square centimeter of normal skin epithelium, each clone
containing between 60 and 30,000 cells [11]. Another study
examined the rate of somatic mutations at a single gene locus
in kidney epithelial cells obtained from organ donors. In
donors from the first decade of life, the rate of mutations
observed was around 0.2 in 100,000 and there was an in-
crease with age such that for donors in their eighth and later
decades the rate was 4 in 100,000 [12]. In addition to the
accumulation of mutations that occurs with age, there is also
an increase in epigenetic modifications in normal tissues that
can then also predispose to malignant transformation, for
example, by the inactivation of tumour suppressor genes.
In the prostate glands from men without cancer it has been
observed that the methylation of promoter CpG islands in
genes implicated in prostate cancer increased with age [13].
A recent study of clonal mosaicism, defined as large struc-
tural genomic events resulting in alteration of copy number
or loss of heterozygocity, in a cohort of 31,717 people with
cancer and 26,136 cancer free controls found that in the latter
the strongest predictor of clonal mosaicism was age with a
frequency of 0.23 % in subjects younger than 50 years
increasing to 1.91 % in subjects aged 75–79 years with
only a slightly higher frequency found in individuals
with cancer and no increased frequency in those with
early onset cancers [14].
Together, this evidence indicates that genetic aberrations,
even major changes, accumulate normally as we age and the
rates at which mutations develop in advanced cancers is very
similar to that in normal cells [15] and hence a cancer genome
may be acquired naturally with advancing age. With around
1013 cells in the body and many millions of cells normally
acquiring the number of mutations sufficient to generate a
malignant genotype by the age of 70, the inevitable conclusion
is that in all individuals who survive into old age, there will
always be plentiful cells with the requisite mutations and
hence capacity to initiate a cancer. The incidence of clinical
cancers is therefore relatively very low compared with the
burden of potential cancer-causing mutations (Fig. 1).
3 Cancer heterogeneity: more than genetic!
In addition to the considerable variation between tumours
(intertumoural heterogeneity) in different individuals, even
those of similar phenotype in the same tissue: it has gradually
become clear that there can also be considerable heterogeneity
within individual tumours and heterogeneity between the
primary tumour and metastatic lesions within any cancer
patient. This intratumoural heterogeneity can arise through a
number of mechanisms. The first source is genetic heteroge-
neity: as the cancer cells pass throughmany rounds of division
the acquisition of further mutations results in the development
of clonal diversity. There then appears to be clonal selection
according to Darwinian principles with clones selected that
have preferred advantages to survive and grow within the
local conditions and environment. The current limitation of
most imaging techniques used to detect cancers is around 1 cm
which equates to approximately 10−9 cells, which when con-
sidered with the average tumour doubling-time, provides an
estimate of around 12 years between cancer initiation and
diagnosis [4]. This represents at least 30 cell doublings with
the potential accumulation of significant genetic heterogene-
ity. Studies on patients with colorectal cancer further indicate
that the transition from an adenoma to a carcinoma may take
10–20 years [15] in which time genetic heterogeneity can
further increase (Fig. 2). A sequencing analysis of multiple
samples taken from four patients with renal-cell carcinomas,
both before and after treatment, revealed considerable
intratumoural heterogeneity [16]. A single tumour biopsy spec-
imen revealed only a minority of the genetic aberrations in the
entire cancer: 63 to 69 % of all somatic mutations were hetero-
geneous and not found in every sequenced region and between
25 and 50 % of nonsynonymous variants identified in single
biopsies were private and not found elsewere in the cancer.
Similar intratumoural heterogeneity has also been reported for
breast cancer where even a single biopsy specimen was found
to contain multiple intermixed karyotypic tumour populations
[17]. Evidence also indicates that metastatic lesions (which
Fig. 1 Epithelial cells in tissues with relatively high cell turnover
accrue a large number of mutations by the time individuals reach their
6th or 7th decade. Elderly subjects harbour many epithelial cells with
the number of mutations sufficient to induce malignant transformation.
Most elderly individuals will as a consequence develop latent, occult
neoplastic growths. In a normal lifespan, relatively few of these growths
develop sufficiently to become clinically apparent cancers, and even
fewer progress to invasive disease: the tip of a very large ‘iceberg’ of
hidden cells with a malignant genome
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eventually result in death) may be derived from a low frequen-
cy subclone that was present in the original tumour [18] which
may therefore not be detected in an original biopsy.
The emerging evidence therefore indicates that concepts
of tailoring personalised medicine and biomarkers according
to an individual’s cancer genome established from a single-
needle biopsy are extremely naïve. The evidence of
intratumoural heterogeneity suggests that most individuals
with epithelial cancers will probably have tens or hundreds
of cancer ‘genomes’ and the genome most evident in an
initial biopsy may not be the one that eventually threatens
the patient’s life.
Currently, the most widely held view is that cancer pro-
gression occurs through multiple steps of acquiring further
genetic changes and clonal selection of those with an advan-
tage [19]. There is however a major paradox with this theory.
The genes that may be selected to confer a growth advantage
within the environment of the primary tumour site may not
necessarily also confer an ability for the cell to be dissemi-
nated to a second, metastatic site where it may enter a long
period of dormancy before again starting to proliferate. It has
long been recognised that primary prostate cancers are gen-
erally multifocal composed of multiple genetically distinct
cell clones. A study of multiple metastatic sites from men
who had died of prostate cancer revealed that most metastatic
lesions appeared to originate from a monoclonal source but
the individual lesions then accumulated a variable number of
subclonal changes [20]. This suggested that disparate meta-
static deposits may have originated from a single subclone in
the primary prostate cancer. There is also evidence that the
metastatic genotype may be acquired early during
tumourigenesis and then other sources of heterogeneity
may drive progression [15, 21]. Indeed there are numerous
normal mechanisms that enable considerable heterogeneity
to develop from a single genotype. Every human develops
from a single fertilised cell to become a complex organism
comprised of billions of cells that can express vastly different
properties and functions: cells such as keratinocytes, bone
cells, lymphocytes and neurons are extremely different from
each other and yet they all possess exactly the same single
genome. Everyone accepts that this incredible heterogeneity
of phenotypes can develop from a single genotype. It then
seems incongruous that when considering why a breast can-
cer cell has a difference in phenotype from a normal breast
epithelial cell (differences that in comparison are relatively
small) explanations seem to require solely a genetic basis and
a series of mutations are sought to explain every change in
phenotype that is required to acquire the hallmarks of a
cancer cell (Fig. 3).
A second potential source of intratumoural heterogeneity
is now recognised to be due to epigenetic changes and
adaptations. Acquired epimutations may in effect be like
genetic mutations in silencing tumour-suppressor genes,
however epigenetic changes may be reversible. As discussed
later, some epigenetic changes may also be heritable and
some may be affected by exposures. A third source of
intratumoural heterogeneity comes from cell differentiation
heirarchies. In an update of the embryonic theory of cancer,
that suggested cancers arise from embryonic cells that are
preserved in adult tissue, it has recently been popular to think
that tumours have rare cells that retain stem cell like proper-
ties that can divide asymmetrically and retain a capacity for
self-renewal. Recent evidence suggests that it is not so ‘black
and white’ but that there are a spectrum of stable states that a
cancer cell can adopt according to epigenetic and phenotypic
stable conditions which the cell can flip between [22]. In a
study of genetically homogeneous clones of human colorec-
tal cancer cells, over multiple serial transplantations in
mouse xenografts, it was found that there was considerable
heterogeneity between the ‘genetically identical’ clones in
terms of proliferation, persistence and chemotherapy toler-
ance. Furthermore these individual clones changed with ex-
posures: following chemotherapy dominant clones emerged
that were previously minor or dormant lineages [23].
It has also recently emerged that there is yet another
source of heterogeneity because of stochasticity in the pat-
tern of gene expression and activity of signalling pathways
within cells [24]. In a traditional experiment, a collection of
cells are exposed to a stimulus or stress and then after a given
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Fig. 2 For most of the common epithelial cancers, there are decades
between the occurrence of the initiating mutations and the appearance
of a carcinoma. For individuals in their 60s or 70s, there are age-related
declines in hormones reducing the drive for the progression of the
neoplastic lesions that occur naturally with aging. The progression of
these occult cancers is sufficiently slow such that within the normal
lifespan of most subjects clinical disease does not have time to develop.
With lifestyle-induced disturbances to metabolic control and the con-
sequent hormonal imbalance, these occult tumours receive signals that
the host organism is in a ‘fed state’ and in the transformed cells this can
activate developmental programs promoting progression. In addition,
these malignant cells are provided with a fertile soil in which to
develop. The process can then be accelerated such that more of the
occult cancers progress to develop clinical disease
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mRNA and proteins which are then analysed to assess
changes in gene expression or changes in activity of signal-
ling proteins. Such an experiment however only gives a
snapshot with a population-averaged and time-averaged re-
sult. However, not all the cells may be the same in that
population, and they may not all be in the same phase of
their response, but techniques limited our ability to obtain
anything other than a population- and time-average re-
sponse. In recent years, techniques for single cell analysis
have enabled assessment of the natural heterogeneity be-
tween seemingly identical cells [25]. An elegant such study
fluorescently tagged nearly 1,000 different endogenous pro-
teins each in an individual, but genetically identical, cancer
cell and then used time-lapse microscopy to follow how the
individual cells respond over time to a common chemother-
apy drug (camptothecin). All cells showed rapid transloca-
tion of proteins between locations within the cells and then
slower waves of protein degradation and accumulation.
However, for a few proteins, the dynamics of change varied
between subpopulations of cells and this related to the phe-
notypic response to the drug. In cells where the levels of two
particular proteins accumulated these cells survived but in
other cells the levels of these two proteins fell sharply and
these cells then self-destructed [26]. Analysis of gene ex-
pression ‘noise’ between individual cells reveals that this can
vary by more than three orders of magnitude and that cells
can slowly fluctuate between metastable states: when a sub-
population of cells were selected for an extreme expression
of a particular protein these cells then slowly repopulated the
original distribution of diverse metastable states [27, 28]. If
in a population of cancer cells a very small subpopulation
exists that expresses high levels of a protein that enabled
those cells to survive when treated with a chemotherapy
agent, then the tumour could be regenerated after a few
rounds of division of these surviving cells.
In response to a stimulus or a change in environment, cell
signalling such as calcium fluxes can be initiated within
seconds, second messenger signalling and protein interac-
tions and modifications including feedback loops then occur
over minutes or hours. Subsequent translocations to the
nucleus then result in modulation of multiple gene transcrip-
tions, epigenetic processes and noncoding RNAs with con-
sequent altered translations leading to changes in protein
concentrations. Finally, as a consequence of all these
changes the result is a cell-fate decision in response to the
original stimulus with cell division, death or differentiation
but these functional changes may not occur until hours or
days after the original stimulus. All of these processes are
complex, highly dynamic and noisy. The noise in these
signalling and gene expression networks appears to fall into
self-organising, stable or metastable patterns analogous to
‘minimum energy equilibrium states’ according to the laws
of thermodynamics. The metabolic context may greatly af-
fect the stable states preferred by cancer cells just as energy
status is central to thermodynamics. Such stochastic hetero-
geneity, with its array of stable states, may provide cancer
cells some plasticity with a mechanism for decision-making
that will determine cell-fate at a tumour level and facilitate a
misguided differentiation process enabling cancer cells to
acquire a malignant phenotype.
The considerable heterogeneity within tumours presents a
formidable challenge and goes a long way to explain many
of the difficulties in treating the clinical disease: any treat-
ment may be very effective at targeting most of the tumour
cells but if a subclone exists that is resistant to that treatment
then however minor the subclone the possibility exists that
these cells will repopulate the tumour and the cancer will
Fig. 3 Within populations of humans there is considerable genetic
heterogeneity between individuals. Within every individual, all of the
somatic cells have an identical single genome but the cells develop
considerable phenotypic heterogeneity: cells of the bone, skin, liver,
nervous system, and immune system can have extremely different
appearance and functions despite all being genetically identical. Within
a tumour, the cells can acquire considerable genetic heterogeneity and a
breast, prostate, or colorectal tumour in one patient can be genetically
very different from that in another patient, partly because of the under-
lying somatic variations between individuals. Despite this considerable
genetic diversity, tumours in the same tissue can manifest similar
phenotypes
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become resistant to that treatment. This presumably contrib-
utes to why the success of so many new targeted molecular
therapies is measured in additional months but not years.
4 Peto’s paradox
Cell sizes have remained roughly comparable across most
metazoans and therefore larger species are comprised of a
greater number of cells. As most cancers arise from the
normal mutation rate which appears to be comparable across
species and as the embryos of all species are initially of
similar sizes then it would be expected that the larger the
species and the longer its lifespan then the higher the prev-
alence of cancer. If mutations accumulate because of repli-
cation errors at every cell division, then the more cell divi-
sions that occur the greater the risk of acquiring a malignant
genotype. Human and mouse embryos are of comparable
size but the adult human is around 3,000-fold larger than
an adult mouse and lives 40 times longer. If every additional
cell division increases the probability of cancer, then humans
should have considerably more cancers than mice. Wild mice
that are reared within a protected environment however die
from cancer at similar rates to humans [29]. Blue whales
have a long lifespan and grow to 1,000 times the size of a
human but are reported to rarely develop cancer [30]. This
would suggest that with the inevitable mutations that would
naturally occur with the many more cell divisions needed to
grow the extra size of larger animals: the larger animals must
have evolved better mechanisms for preventing these from
resulting in lethal cancers. Richard Peto [31] originally posed
this paradox and although numerous potential mechanisms
have been suggested to explain this paradox none have yet
been proven [32]. The paradox could be explained by more
mutations being required for carcinogenesis in larger animals
or larger animals having evolved more tumour suppressor
genes; comparisons between mice and humans have howev-
er revealed that in both cases the numbers are comparable
[33]. One of the most plausible theories for the relatively low
rates of cancers in larger species is related to the inverse
correlation that exists between body size and metabolic rate
[34]. As animals have evolved larger bodies, the physical
problems of supplying nutrients and oxygen to more expan-
sive and distant tissues has been compensated for by a lower
basal metabolic rate reducing these demands. It has been
postulated that as the generation of reactive oxygen species
(ROS) is a byproduct of metabolism and ROS can induce
DNA damage therefore the reduced metabolic rate in larger
animals should result in lower mutation rates [32]. An ex-
amination of the frequency of mutations in mouse kidney
epithelial cells at the same gene locus that had been exam-
ined in humans however revealed that mutation rates are
roughly comparable [35]. However, as discussed throughout
this review, there is an accumulation of evidence indicating
that metabolism is a critical determinant of carcinogenesis
and therefore a lower metabolic rate may provide a solution
for Peto’s paradox.
5 Genes in context
The concept that gene mutations play a determining role in
the generation of cancer has become ingrained since the
demonstration that the introduction of DNA extracted from
cancer cells into normal mouse fibroblasts transformed these
cells into cells that could form tumours [36]. It is however
well recognised that gene mutations that are known to con-
tribute to cancer within specific tissues may occur exactly the
same in other tissues without such an effect and hence the
mutations per se are not sufficient to cause cancer. The
importance of the local tissue environment for a transformed
cell to become a cancer is indicated by genetic cancer syn-
dromes caused by highly penetrant mutations; such as
Bloom syndrome, neurofibromatosis and BRCA1/2 muta-
tions [37]. Even in such syndromes where there is a clearly
identified heritable risk, despite these mutations occurring
throughout the whole body, they only result in cancers within
specific tissues where presumably the milieu provides the
favourable setting. In all other tissues, the presence of these
mutations do not result in tumours and therefore by them-
selves the mutations alone are not sufficient to cause cancer.
Even germline mutations in instability genes only result in
increased susceptibility to cancers in specific tissues despite
being present in every cell and contributing to general DNA
maintenance mechanisms. For example mismatch repair
(MMR) genes have an identical role in every cell throughout
the body but inherited defects in MMR genes result in
susceptibility to tumours in the colon and endometrium but
not in other tissues with rapidly dividing cells such as the
small intestine and bone marrow [38]. Similarly inherited
mutations in BRCA1/2 genes predispose to cancers of the
breast, ovary and prostate and to a lesser extent pancreas and
colon but not lung or bone [39]. Somatic mutations are also
tissue specific in their effects. Mutations in KRAS2 can
initiate the development of pancreatic cancer [40] but the
same mutations may result in hyperplasia in the colon [41] or
borderline lesions that do not progress to carcinomas in the
ovary [42].
Stepping back from the genes within a cell to take a
broader perspective of the cells themselves, it is also clear
that how a cell behaves is dependent on its context within a
tissue and this also applies to cells that possess potential
cancer contributing mutations. There has been extensive
consideration of how a tissue environment affects the behav-
iour of cancer cells [43]. That the microenvironment is of
critical importance is highlighted by different experiments in
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which cancer cells have been transplanted into normal tissues
and the neoplastic phenotype has been shown to be reversible.
Exposure of metastatic human melanoma cells to an embryon-
ic zebrafish microenvironment resulted in a re-programming of
the melanoma cells to a non-tumourigenic phenotype, indeed
melanoma cells implanted into zebrafish embryos were still
present 3 months later but remained dormant and unable to
form tumours. The same cells transplanted into zebrafish just
2 days later, after morphogenesis and organogenesis were
complete, however formed tumours [44]. The injection of the
Rous sarcoma virus (RSV) into the wings of chickens also
produces large and lethal malignant tumours but injecting RSV
into the wings of early chick embryos did not induce tumours
and the embryos continued to develop normally; but if those
embryonic chicken wings were removed and dissociated in a
culture dish then they rapidly developed a transformed pheno-
type [45]. The effect of a normal tissue environment on cancer
cells and how this may change has been elegantly demonstrat-
ed by inducing mammary tumours in rats by injection of N-
nitrosomethylurea (NMU); 50,000 of the resultant cancer cells
from these donor rats were then introduced into cleared fat
pads of host rats of varying ages and also into rats that had been
through two cycles of pregnancy, lactation and involution. Six
months after inoculation, tumour incidence in the host rats
varied considerably dependent on the age of the host: from
100 % in 52-day-old rats to 18.2 % in 150-day-old rats but no
tumours at all occurred in the twice-parous rats [46].
The dogma that mutations alone were sufficient to cause
epithelial cancers has also been challenged by experiments in
which epithelial and stroma cells were separately exposed to
carcinogens. The transplantation of rat mammary epithelial
cells that were previously exposed to the NMU into cleared
fat pads of rats failed to form tumours but formed phenotyp-
ically normal ducts. If the stroma was however exposed to
NMU then neoplastic transformation of the mammary epi-
thelial cells was observed regardless of whether the epithelial
cells were exposed to NMU or not [47]. When a non-
tumourigenic mouse mammary epithelial line was also
transplanted into cleared fat pads of mice, tumours were
formed in 81 % of mice that had previously been exposed
to gamma-radiation prior to the transplantation but only
19 % if the mice had not been irradiated and the tumours
were larger and developed earlier in the irradiated hosts [48].
All of these experiments indicate a malignant genotype
only results in tumours in certain contexts and that in other
contexts the phenotype can be completely reverted despite
the same cancer genotype. A malignant genotype itself is
therefore not sufficient to generate a tumour but also needs
an appropriate context. The same underlying principle was
proposed well over a century ago to explain why different
tumours predominantly metastasised to very specific tissues.
The English surgeon Stephen Paget suggested that the dis-
tinct sites of metastasis were not only dependent on the
disseminated tumour cells, the ‘seed’, but also depended on
the ‘properties of the soil’: the appropriate tissue microenvi-
ronment that would enable the seed to grow and develop
[49]. From the evidence described above, the same principle
appears to apply at the primary site: the cancer genotype will
only develop into a tumour phenotype if the tissue microen-
vironment is appropriate. This same principle has been pro-
posed to explain why occult tumours that normally occur in
most people only progress to clinical cancers in relatively
few individuals [50]. It may also help explain the long
recognised issue of clinical cancer dormancy: following
removal of the primary tumour, residual cancer cells can
remain in the body for decades without the development of
clinical cancer but then relapse after a protracted period of
‘dormancy’ [51]; for example, 20 % of women treated for
breast cancer who are disease free, then relapse 7 to 25 years
following the original mastectomy with a relatively steady
rate of recurrence even after such a long period [52]. This
again indicates that cells with a malignant genotype can exist
for long periods within the body but only elaborate the
malignant phenotype when the context is appropriate. The
observation that as rats age the ability of inoculated breast
cancer cells to form tumours decreased [46], suggests that
the ‘soil’ changes with age. With the inevitable accumulation
of genetic damage that naturally occurs with age, such a
change could represent a defensive adaptation to prevent
cancers from progressing.
6 From genes to pathways
Cancer is an acquired genetic disorder due to an accumulation
of gene mutations: it has however become clear that the
number of mutations that tumours harbour can be very large,
as indeed are present in normal tissues, with a very diverse
pattern of mutations even in similar tumours [5, 6]. With a
recognition of the prevalence of mutations, it has been pro-
posed that even mutations in oncogenes, tumour suppressor
genes or genetic instability genes should be regarded just as
contributing to cancers rather than as causing cancers [3]. The
observation that most cancers do not have an abnormally high
mutation rate, but the measured number of mutations is rough-
ly equal to that expected in somatic cells having passed
through many rounds of cell division acquiring mutations at
the normal mutation rate, indicates that defects in instability
genes are not common in the widespread non-hereditary can-
cers. Germline mutation in these instability genes however
result in cancer predisposition and these contribute to the most
common syndromes of hereditary breast and colon cancers.
The huge variety of mutations observed in similar tu-
mours originating from the same tissues indicates that many
different genotypes can result in the same phenotype (Fig. 3).
When this diversity was recognised it was proposed that one
Cancer Metastasis Rev (2013) 32:673–705 679
explanation could be that the genes were organised into much
fewer number of intracellular pathways and it was the distur-
bance of these pathways that was driving carcinogenesis [53].
When technology was developed such that comprehensive
sequencing of genes across the entire genome became feasible;
the pattern of mutations observed indeed fitted this model.
After analysing the sequences of 20,857 transcripts from
18,191 genes in 11 breast and 11 colorectal cancers the authors
characterised the mutational landscape identifying frequently
mutated genes that were termed ‘mountains’ and the less
frequently mutated genes termed ‘hills’ [6]. The ‘mountains’
were the well-known oncogenes and tumour suppressor genes.
These gene mutations occured relatively early in the course of
cancers andwere not specifically associatedwith themetastatic
stage which is the cause of most cancer deaths [3]. The ‘hills’
were described by the authors as dominating the landscape and
the diversity in the ‘hills’ was not hopelessly complex but
predominantly grouped into a small number of cell signalling
pathways: with the phosphatidylinositol-3 kinase (PI3K) path-
way being the most prominent [6]. Genes within the PI3K
pathway have been found to be altered in more than 30% of all
colon and breast cancers [54]. From the considerable evidence
emanating from studies of the cancer genome it was concluded
that it was these ‘signalling pathways rather than individual
genes’ that determined the course of tumourigenesis [3]. This
indicated a major shift in emphasis in how we should consider
the development of these common cancers.
7 From pathways to programs
With a large burden of genetic damage naturally accruing as
we age, there are many mechanisms that have evolved to
prevent these from resulting in fatal cancers and it is now
clear that for a cancer to develop there are a number of
essential controls that have to be overcome. These were
originally described as the six hallmarks of cancer [55],
and these have recently been updated with a further four
hallmarks [56]. All of the described properties essential for
carcinogenesis are not however novel properties specific to
cancers but are properties that in some tissues, at some stages
of life are perfectly normal; for example, increased cell
proliferation, increased energy metabolism, evasion of
growth suppressors, evasion of contact-inhibition, evasion
of cell death, invasion, metastasis and induction of angio-
genesis are all important steps in cancer progression but in
early foetal life all of these processes are a normal and
essential requirement for development and morphogenesis.
Furthermore, during foetal development these processes are
all integrated in a developmental program. Indeed one of the
early concepts of cancer was that it was initiated from
embryonic-like cells or embryonic ‘remnants’ [57] in which
this program was reactivated. Some of these processes are
maintained in normal tissues throughout the lifespan: for
example the constant renewal of epithelial surfaces requires
cell division and migration of cells from the basal to the
surface layer: indicating that there are varying combinations
of properties that may be programmed together. The integrity
of the organism is dependent on the ability of epithelial
surfaces to repair when wounded. Wound healing involves
cell proliferation, migration, inflammation and angiogenesis:
all processes fundamental to tumour progression. Indeed
tumours have been likened to wounds that do not heal [58]
or even to wounds that over-heal [59]. The wounding of an
epithelial surface has been reported to result in an instanta-
neous generation of an electric field that guides cell migra-
tion and the wound healing process and this signal is medi-
ated via the PI3K pathway [60]. As described in the other
sections of this review, this pathway also appears to play an
important role in epithelial carcinogenesis.
In amphibians not only can epithelial surfaces be repaired
but whole limbs can be regenerated: which indicates that the
cells retain the plasticity to be able to reactivate the whole
morphogenesis program that normally only operates in early
development. This involves the formation of a blastema at
the site of injury that then has the ability and plasticity to
grow and differentiate into all of the different tissues that can
then form a new limb. In species that retain this ability for
regeneration, there appears to be an inverse relationship
between tissues able to regenerate and those that can support
the development of tumours. Studies in newt, salamander
and axolot established that it was difficult to induce cancers
and these only occurred in tissues that lacked the ability to
regenerate and in contrast tissues that could regenerate, such
as limbs and tails, were extremely resistant to cancer [61,
62]. Thus, it appears that tissues that retain the plasticity and
ability to reactivate the program for morphogenesis do not
provide the context, or soil, in which a cancer can progress.
The various hallmarks of cancer are not specific
distinguishing properties of cancer cells; they are all active
in normal tissues at varying stages throughout the lifespan
but in a tightly controlled manner to ensure that tissues
throughout the body function in a highly organised manner.
What distinguishes cancers is that these programs are
reactivated inappropriately and evade the normal controls.
For a malignant cell to acquire all of the hallmarks of cancer,
a separate defect to overcome all of the many individual
controls is not required: it just requires reactivation or co-
opting the program that is activated normally during early
development or during wound healing.
8 From prevalent mutations to prevalent occult cancers
In a similar manner to the general under-appreciation of the
prevalence of gene mutations: there is also a lack of
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appreciation of the true prevalence of cancer in the general
population. In reality virtually every individual has small
tumours in their body by the time that they get to their sixth
or seventh decade of life although in most these lesions never
progress to clinical disease. This has been referred to as
‘cancer without disease’ [63]. The prevalence of these latent,
occult tumours in the general population has traditionally
been assessed by autopsy studies of individuals who had
died of causes other than cancer but this evidence has been
substantiated for colorectal cancer by population colonosco-
py screening studies and for prostate cancer by large cohort
studies that have involved the taking of prostate biopsies.
The common cancer with the least available evidence is
breast cancer for which only a few, relatively small, autopsy
studies have been published [64]. Although the results have
been somewhat variable: the largest studies have only been
of a couple of hundred women and the methodology has
varied considerably in relation to sampling method and the
extent to which the breasts were investigated. The prevalence
of cancers detected appeared to be strongly dependent on the
number of histological sections examined. The most thor-
ough histopathological study of breasts obtained at autopsy
in Denmark examined an average of 275 paraffin blocks per
breast: for women between the ages of 40 to 50 years not
known to suffer from breast cancer when alive: 39 % were
found to have ductal carcimonas in situ and another 12% had
atypical ductal hyperplasia [65]. Studies examining much
smaller numbers of sections found less cancer. In contrast
the prevalence of colorectal cancer in the general population
has been examined in many autopsy studies and also increas-
ingly in screening colonoscopy studies. A comparison of the
two different types of study indicated reasonable agreement
with an increase prevalence of adenomas detected with age;
by the age of 70 years the mean prevalence of adenomas
detected by autopsy studies was 42 % and that detected by
colonoscopy studies was 37 % with hyperplastic polyps also
detected by autopsy in 28 % and by colonoscopy in 31 %
[66]. A recent colonoscopy study investigating subjects at
increased risk for colorectal cancer using a magnifying co-
lonoscope found that for individuals in their early 60s, each
had a median of 6 aberrant crypt foci, small growths in the
colon, and the number was associated with the subsequent
risk of colorectal cancer [67].
Even more extensive data are available for occult prostate
cancers, again autopsy studies reveal a very high prevalence
of latent cancers in the general population [68]. Reports
indicate a steady increase with age [69] such that latent
cancers were detected in up to 80 % of men aged over
90 years [70]. A recent autopsy study compared American
men of African descent with those of European descent. The
same pathologists examined prostates obtained from 1,056
men and, despite men of African descent having a 60 %
higher incidence of clinical prostate cancer and 2- to 3-fold
higher mortality, the rates of latent cancers detected at au-
topsy were identical irrespective of ancestral descent [71].
Latent cancers were even found in men in their twenties (8 %
of men of African descent and 11 % of men of European
descent) and by their seventh decade the prevalence had
increased to 77 % in men of African descent and 69 % in
men of European descent [71]. This study indicates that the
higher rates of prostate cancer incidence and mortality in
African American men is not due to more cancer initiation.
The high incidence in African American men contrasts with
the very low incidence within populations of western Africa,
from where the ancestors of African American men origi-
nate, indicative that the high incidence is likely not due to
genetics but more likely due to environmental exposures
[72]. Further evidence for the general high prevalence of
latent prostate cancers comes from data from biopsies taken
from men with normal PSA and digital rectal examinations
in the Prostate Cancer Prevention Trial. The prevalence of
latent cancers detected from biopsies (15.2 %) was lower
than comparable autopsy series (18.5 to 38.8 %) [73, 74], but
this difference would be expected because of the under-
detection rate when comparing small biopsies with whole-
mount prostate gland analysis.
These are examples of studies examining specific tissues
but if we consider all epithelial cells throughout the body then
it seems clear that all elderly individuals will have one or more
latent occult cancers somewhere in their body. Lesions that
occur in up to 80 % of all men in the population who survive
into old age are, by definition, normal and the evidence clearly
indicates that occult tumours within epithelial tissues is a
normal feature of aging. This evidence is entirely consistent
with the evidence indicating that large numbers of cells will
have acquired sufficient mutations to generate a cancer ge-
nome in most elderly individuals (Fig. 1).
9 Metabolism and the PI3K pathway
From the above evidence, it is clear that as we age there are
many cells in the body that naturally acquire a genotype that
could contribute to cancer but the progression of a cancer
depends on the disturbance of cell signalling pathways and
the reacquisition of a program that enables it to acquire all of
the hallmarks of cancer. Programs similar to those active in
early development and wound healing need to be activated to
overcome the controls that normally maintain tissue homeo-
stasis. Furthermore it seems that the PI3K pathway plays an
important role both in wound healing and in tumourigenesis.
If we again step back from just considering cancer cells and
take a broader view of this pathway and its general role it is
clear that it has played a very fundamental role in animals
that has been maintained throughout evolution. The ability to
control growth and development according to the availability
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of nutrients provides a survival advantage and therefore has
been selectively retained throughout evolution. The ability to
delay growth and reproductive development at times when
food is scarce enables the organism to survive until more
food becomes available and it can then grow, develop and
produce offspring when food is again abundant. Evidence
has accumulated to indicate that the PI3K pathway provides
this control in all species from yeast to mammals. In lower
species, such asCaenorhabditis elegans, when food is scarce
the pathway is switched off and the organism goes into a
dormant phase until food is again available and lifespan can
be dramatically prolonged to ensure survival through such
periods of prolonged famine [75]. The effect on lifespan of
suppressing the PI3K pathway appears to have been then
conserved throughout evolution [76]. Various forms of the
PI3K enzyme exist that are classified into three groups
(classes I, II and III). Only one of these forms is present in
yeast and is equivalent to mammalian class III PI3K, which
in yeast is termed VPS34: this acts as a nutrient sensor and is
directly activated by the availability of amino acids and then
itself activates mTOR/S6K1 to regulate cell growth and
development [77]. In mammals, class 1A PI3K has evolved:
this form is not directly activated by nutrients but consists of
heterodimers comprising a regulatory subunit and a catalytic
subunit that enables the enzyme to be controlled by receptor
tyrosine kinases, classically the insulin and insulin-like
growth factor receptors (IR and IGF-IR) [78]. This enables
systemic signals between the community of cells within
metazoans to synchronise these fundamental controls ensur-
ing that all growth and development throughout the organ-
ism occurs appropriate to the availability of nutrient sub-
strates. It is not by chance that the insulin/IGF/PI3K pathway
plays a fundamental role in regulating both metabolism and
growth as it clearly is an advantage to synchronise these two
processes and this synchronised control has been maintained
throughout evolution. Early human development is also
tightly regulated according to nutrient availability by the
insulin/IGF axis [79] ensuring that growth and development
only proceeds when the cells receive the appropriate signal,
activating the PI3K pathway, and this signal provides an
indication to the tissues that the organism is in the ‘fed state’.
As cancer cells reactivate a program analogous to that active
in early development, it is not surprising that this fundamen-
tal control is also engaged. Indications that the PI3K pathway
is critical for the progression of epithelial cancers suggests
that this is indeed the case and that these cancers are more
likely to progress if they are receiving a signal that the
organism is in the ‘fed state’ and hence energy and substrates
are available (Fig. 4a). As the cancer progresses and the
tumour cells evade the normal social signals and become
more autonomous then this signalling pathway may become
constitutively activated in the cell because of genetic or
epigenetic alterations (Fig. 4b).
10 Cancer metabolism and oncogenes/tumour
suppressor genes
A cancer is by definition cells that have acquired a growth
advantage: rapid growth is dependent on an increase in
supply of energy and of substrates for the biosynthesis of
all the macromolecules that are required to build new cells.
In normal tissues in an adult, in cells that are not proliferating
metabolism is geared up to obtain maximum energy from
metabolic fuels. The most available metabolic substrates in
the body are glucose and glutamine (which is the most
prevalent amino acid). The most efficient generation of en-
ergy from glucose occurs by via glycolysis to pyruvate
which then is fed into the tricarboxylic acid (TCA) cycle in
the mitochondria where the carbon is eventually burnt down
to carbon dioxide through oxidative phosphorylation. The
initial glycolysis yields 2 molecules of ATP from every
molecule of glucose and the TCA cycle eventually yields a
further 34 molecules of ATP. More than 80 years ago the
German biochemist Otto Warburg observed that cancer cells
did not metabolise glucose in this way but instead fermented
glucose to lactate; a process originally described by Louis
Pasteur and thought to occur in the absence of oxygen and
therefore no substrate for oxidative phosphorylation. In can-
cer cells, this however occurs even when adequate oxygen is
available and is referred to as aerobic glycolysis. Initially this
seemed very inefficient as it yields only 4 molecules of ATP
per molecule of glucose. It was however subsequently been
realised that this metabolic switch was required in prolifer-
ating cells because rather than burning all of the carbon down
to CO2: the carbon backbones from glucose were needed to
be fed into the TCA cycle where they were required for
building all the new macromolecules required to duplicate
the cell. In proliferating cells glucose and glutamine must not
only supply the energy requirements but must also supply the
building blocks and some of these substrates therefore have
to be diverted to supply macromolecular precursors such at
acetyl-CoA for the synthesis of fatty acids and lipids, glyco-
lytic intermediates for the synthesis of amino acids and
ribose for the synthesis of nucleotides. The additional energy
required is then obtained by increased flux through glycoly-
sis. This is not only a requirement for proliferating cancer
cells, but also for embryonic development and for cells in
normal tissues that continue to proliferate throughout adult
life. Thus proliferating lymphocytes in response to infection,
switch to aerobic glycolysis [80, 81] and during wound
healing cells switch to aerobic glycolysis [82]. It was subse-
quently surmised to be a requirement for enterocytes, lym-
phocytes, thymocytes, tumour cells and indeed all rapidly
dividing cells [83]. The high flux of glucose and glutamine
was also suggested to not only provide necessary energy and
biosynthetic precursors for cell division but in addition en-
abled more sensitive regulation of proliferation rather than
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just relying on regulation of cell metabolism via allosteric
effects of metabolites on rate-limiting enzymes [83].
Following the description of the ‘Warburg effect’, there
was considerable interest over the subsequent decades in this
metabolic switch that is fundamental for cancer develop-
ment. This interest however then waned; as the research
focus became dominated by oncogenes and tumour suppres-
sor genes. Interest has however recently been reawakened
through findings in a number of different fields [84, 85].
Indeed the importance of the metabolic switch to aerobic
glycolysis for proliferation even in normal cells appears to
have been rediscovered [86].
The evolutionary advantage, of being responsive to nutrient
availability, was originally acquired in single-cell organisms by
key enzymes in metabolic pathways that were able to directly
sense nutrient concentrations. In mammals, cells within most
tissues are however provided with a relatively constant nutrient
supply sufficient to support proliferation and the individual
cells are no longer autonomous but are part of a large commu-
nity and their proliferation is accordingly tightly regulated by
communal signals. The PI3K pathway appears to be the critical
regulator that mediates the response to growth factors and
enables the appropriate switch in cell metabolism [78, 87].
The form of PI3K that is present in single cell organisms is
directly activated by nutrients whereas the form present in
metazoans is activated by growth factor receptors: enabling
synchronised response to nutrient availability across the pop-
ulations of cells within multi-cellular organisms. Activation of
the PI3K pathway is sufficient to induce the Warburg effect,
switching metabolism to aerobic glycolysis in both normal and
a b
Fig. 4 a The PI3K pathway is the evolutionary conserved signalling
pathway to ensure that growth and development is synchronised to the
appropriate metabolic conditions: energy and substrate requiring pro-
cesses only proceed when a ‘fed state’ is indicated. In metazoans, the
insulin/IGF receptor modulates the activity of the PI3K pathway
according to social signals indicating metabolic status throughout the
organism. Growth and development is regulated, along with nutrient
partitioning, and appropriate signals from the extracellular matrix
(ECM) that are integrated via integrin receptors that associate with the
insulin/IGF receptors in the cell membrane. b Perturbed metabo-
lism and insulin/IGF activity can reprogram cell behaviour via
modifying FOXO transcription factors: promoting epithelial mes-
enchymal transition and activating developmental cell programs
resulting in cells adopting a metastatic phenotype. Mutations in
the PI3K pathway and loss of PTEN can result in constitutive
activation of the pathway promoting more autonomous control,
less dependent on external signals, and further promotes progression and
metastasis
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cancer cells [88]. Activation of PI3K increases the cell surface
abundance of transporters that enhance the uptake of glucose,
amino acids and other nutrients; it also activates hexokinase
and phosphofructokinase-1 channelling glucose through the
glycolytic pathway and in addition it directly stimulates lipo-
genesis [89] and viamTOR it stimulates protein synthesis [90].
The final rate-limiting step of glycolysis, which generates ATP,
is catalysed by pyruvate kinase. Pyruvate kinase exists in
multiple isoforms: it was proposed that PKM2 was present in
embryonic tissues but this was progressively replaced by
PKM1 that then became the predominant form in most differ-
entiated cells in adults. However PKM2 may become re-
expressed in most cancer cells and counter-intuitively PKM2
has lower enzyme activity than PKM1 [91]. While PKM1 is a
constitutively active enzyme, in contrast PKM2 is regulated by
tyrosine kinases that induce the release of an allosteric activator
(fructose-1,6-bisphosphate) resulting in inhibition of PKM2
activity [92]. The presence of the PKM2 isoform enables the
Warburg effect and a switch in metabolism by slowing glycol-
ysis and facilitating the shunting of carbon substrates into
biosynthetic pathways [93]. The implication that cancer cell
metabolism may be driven by a tumour specific PKM2 raised
the prospect of an attractive therapeutic target but then further
work indicated that PKM2 was also the predominant isoform
present in matched normal tissue [94] as had indeed been
observed many years earlier [95].
Following decades when the focus has been dominated by
interest in mutations in oncogenes and tumour suppressor
genes as drivers of autonomous cancer cell growth, a resur-
gence of interest in cancer cell metabolism has partly arisen
from observations that many of these oncogenes and tumour
suppressor genes actually control elements of the metabolic
switch that has to occur in cancer cells. The tumour suppres-
sor gene PTEN (phosphatase and tensin homolog deleted on
chromosome ten) was originally described as being frequent-
ly mutated in brain, breast and prostate cancers [96] and it is
also the most frequently deleted gene in many human can-
cers [78]. It has subsequently become clear that PTEN is a
lipid phosphatase that dephosphorylates the product of PI3K
and hence directly opposes PI3K. Loss of PTEN therefore
results in unopposed PI3K activity and activation of the
Warburg effect as described above. Another tumour suppres-
sor gene that is frequently inactivated in human cancers due
to mutations is p53 which has been reported to induce TP53-
induced glycolysis and apoptosis regulator an enzyme that
degrades 2,6-fructose bisphosphate, which is an allosteric
activator of phoshofructokinase 1 (PFK1) the enzyme that
redirects glucose into the pentose phosphate pathway [97].
Loss of p53 therefore results in increased activity of PFK1
leading in turn to increased glycolysis. At the same time it
was shown that p53 also induces cytochrome C oxidase 2 an
enzyme that enhances mitochondrial respiration [98]. There-
fore loss of p53 results in both reduced mitochondrial
respiration and increased glycolysis as per the Warburg
effect. In the same year that PTEN was discovered the c-
Myc oncogene was also linked to the regulation of tumour
metabolism with a report that c-Myc activated lactate dehy-
drogenase and this was required for tumour growth [99]. It
has subsequently become clear that c-Myc regulates many of
the enzymes involved in glycolysis [100] and also affects
many genes involved in glutamine catabolism [101] and
furthermore stimulates mitochondrial biogenesis [102].
Although it has become apparent that many oncogenes
and tumour suppressor genes may elicit the Warburg effect in
a cell autonomous manner [103], it is clear that the regulation
of the metabolic switch enabling cells in metazoans to enter
proliferative cycles is fundamentally regulated by growth
factor signalling. From the evidence described in the previ-
ous sections, it is clear that while gene mutations initiate
cancers: for them to then progress, the ‘seeds’ need to be in
the right ‘soil’ and a signal indicating that the cells can
switch metabolism to that appropriate to a ‘fed state’ is
critical for their growth. It seems that many tumours, at least
initially, still respond to the communal metabolic signals
(particularly the main activators of the PI3K-pathway, insu-
lin and IGFs) and these signals may constitute part of the
context that enables the cancer to progress: indicative that the
‘soil’ is fertile. With progression however this pathway often
eventually acquires constitutive activation (Fig. 4b).
11 Heritability of common epithelial cancers
The extent to which the common cancers are heritable is a
further area of general misconception. The genetic contribu-
tion to the risk of common diseases has conventionally been
assessed in twin-cohort studies comparing the incidence of
disease in monozygotic twins (who share all of their genes)
with dizygotic twins (who share 50 % of their segregated
genes). Such a study of breast, prostate and colorectal can-
cers in a very large cohort of twins in Scandinavia found the
risk attributable to genetic factors to be much lower than that
attributable to environmental exposures [104]. The estimated
proportion of risk due to heritable factors was 27 % for breast
cancer, 42 % for prostate and 35 % for colorectal cancer. The
analysis of this study was subsequently updated with genetic
susceptibility modelling yielding heritable fractions of 12 to
30 % for breast cancer, 16 to 45 % for prostate cancer and 8
to 27 % for colorectal cancer [105]. The twin studies are
based on a number of assumptions and clearly most twins
share not just their genes but they also share considerable in
respect to common life-exposures. In basic twin models
gene-environment interactions are assumed not to exist or
they are included as part of the genetic variance inflating
heritability estimates [106]. Another approach has been to
examine family databases. An analysis of the Swedish
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Family Cancer Database examined a population of 9.6 mil-
lion with over 700,000 cancers. The estimated genetic com-
ponent of risk was 25 % for breast cancer, 13 % for colon
cancer and 12 % for cancer of the rectum; prostate cancer
was excluded from the analysis [107]. Studies from this large
database suggest that at least part of the familial clustering
observed for these common cancers could be explained by
shared lifestyle-related factors. An elegant alternative ap-
proach to estimating the contribution of genetic and environ-
mental influences on cancer was undertaken by assessing
cancer risk in individuals who were adopted very early in
life. Such individuals have two sets of parents: their biolog-
ical parents, from whom they inherited all of their genome
but shared none of the family environment and their adopted
parents, with whom they share no genetic relationship but
with whom they shared the family environment. In a cohort
of 960 such adoptees the relative risk of cancer was studied
in relation to whether one of their parents had died of cancer
by the age of 50. The risk of cancer in those individuals
where one of their biological parents had died of cancer was
1.19 whereas the relative risk associated with a cancer mor-
tality in one of their adoptive parents was 5.16 [108]. This
approach is also complicated by many potential confounding
factors but again it suggested that shared exposures had a
much greater effect on the risk of these common cancers than
shared genes. More than 90 % of the common epithelial
cancers are sporadic with only a small proportion being
associated with a family history.
12 Missing heritability
Following the evidence from classical epidemiology that
suggested a significant familial aggregation of the common
epithelial cancers and with the advances in sequencing tech-
nology there have been many large efforts to identify the
genes that may be responsible. Although some genes have
been identified such as BRCA1/2 for breast cancer and APC
for colorectal cancer that account for a small proportion of
these familial cancers the search for additional highly pene-
trant genes has largely been unsuccessful. After the initial
genome-wide association studies investigating associations
between single-nucleotide polymorphisms and common dis-
eases, it was acknowledged that only a very small proportion
of observed familial clustering was explained [109] and
attention began to focus on the ‘missing heritability’ [110].
The major efforts of subsequent work have been to identify
undiscovered variants with the hope that rare causative var-
iants could be discovered by increasing the power with next
generation sequencing, larger cohorts, consortiums and
meta-analyses. These have still however only revealed
markers that confer relatively small increments of risk and
only explain a small proportion of the observed familial
clustering of common diseases. There has also been a reali-
sation that the original expectations were over optimistic,
some were based on misplaced preconceptions and others
were somewhat naïve: it is clear that the causes of diseases
such as the common epithelial cancers are very complex
[111]. The contribution of gene–gene, gene–environment
and epigenetic variation may all contribute to disease risk
and remain challenging to assess. That one gene may act on
or modify the effects of another gene (epistasis) has been
recognised for a long time but the complexity of gene net-
works and biochemical systems and how they affect genetic
analyses are just beginning to be unravelled [112, 113].
Despite the implications that epistasis may be important,
the available data thus far suggest that most gene interactions
are merely additive [114] and where multiplicative interac-
tions exist they only contribute a modest effect for prostate
cancer [115] and for breast cancer [116].
A further confounding factor has been the heterogeneity
of phenotypes with studies examining genotypes with breast,
prostate or colorectal cancers although it is now recognised
that each of these may represent a broad array of cancers that
affect the same tissue and that genes may have different
effects on the initiation and progression of these different
diseases. Evidence is emerging consistent with both of these
issues confounding many of the earlier studies. Low pene-
trance genetic loci have been found to be associated with
specific clinical subtypes of breast cancer consistent with them
having different biological origins and hence different herita-
bility [117]. Genetic variants identified to be associated with
risk of breast cancer have also been found not to be associated
with breast cancer survival indicating that different heritable
genes are involved in initiation and progression [118].
The evidence thus far does not indicate that a large com-
ponent of the missing heritability will be explained by rare
variants with large effects or by gene-gene interactions, but
there is still much to be learned about the contribution of
epigenetic factors. Variations in protein expression and func-
tion are not only determined by variations in DNA sequence
but may also be affected by many epigenetic mechanisms
such as DNA-methylation and histone-modifications, a com-
bination of many small and micro-RNAs, RNA-binding
proteins and RNA-editing enzymes. Reports of epigenetic
changes in cancer, including all of the above factors, have
been increasing exponentially over recent years [119–121].
The IGF-II gene is epigenetically imprinted with only the
paternal allele normally expressed but loss of IGF-II imprint-
ing has been found to be a common occurrence in many solid
tumours. Furthermore, there have been observations that this
loss of imprinting occurs not just in the cancer cells but as a
field effect with loss of imprinting also in the surrounding
normal tissue. Loss of IGF-II imprinting has been reported in
the normal colonic mucosa of around 30 % of patients with
colorectal cancer [122] and loss of IGF-II imprinting has
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been observed also throughout the normal prostate in just
under 40 % of men with prostate cancer [123]. The loss of
IGF-II imprinting has been associated with augmented acti-
vation of the PI3K-pathway [124] and hence the reports of a
field epigenetic effect may indicate that this could be a
predisposing factor for these cancers. That epigenetic
changes may be causally contributing to cancers is supported
by the developmental loss of IGF-II imprinting being asso-
ciated with the most common solid cancer in childhood,
Wilms’ tumours [125] and also with the constitutional loss
of IGF-II imprinting in Beckwith–Wiedemann syndrome
being associated with an increased risk of cancer [126].
Genetic variation may affect a number of these factors; for
example single-nucleotide polymorphisms within
microRNA have been proposed to affect the risk of breast
cancer via the effects of these microRNA [127]. There is also
considerable evidence that some of the epigenetic modifica-
tions may themselves be conserved across generations [128,
129]. The methylation of the IGF-II gene, which is associat-
ed with the imprinting of this gene, shows familial clustering
across three generations suggesting that genetic factors may
play a role in epigenetic modifications of IGF-II [130]. Some
of the missing heritability may therefore be due to epigenetic
inheritance.
It has however also become evident that at least some
forms of epigenetic inheritance are affected by environmen-
tal exposures [131, 132]. This additional layer of complexity
blurs the distinction between inherited and acquired varia-
tion in that environmental exposures may induce epigenetic
variations that are expressed several generations later; for
example, nutritional exposures during pregnancy can result
in transgenerational effects on cancer susceptibility by in-
ducing changes in the DNA-methylating pathways which are
passed on down several generations [133]. A high fat diet
during pregnancy in mice has been reported to affect pheno-
type into the third generation of offspring via affects on
imprinted genes [134]. Supplementing the diets of pregnant
mice with methyl donors has also been found to induce DNA
hypermethylation which attenuated a predisposition to obe-
sity in successive generations of offspring [135]. This meth-
od indicates that some of the heritable component of these
cancers may indeed be due to environmental exposures
acting across generations via epigenetic mechanisms. The
interactions between genetic and environmental effects on
the epigenome have been elegantly illustrated in studies of
monozygotic twins and family cohorts. Identical twins have
remarkably similar epigenomes early in life but variations
increase with age and twins who spent less of their lives
together or who had more differences in natural health and
medical history showed the greatest divergence [136, 137].
A study of longitudinal intra-individual changes in DNA-
methylation, including a family based cohort, observed both
global and gene-specific variations over time but with some
familial clustering of methylation change [138]. This could
indicate that within families there were common exposures
that affected epigenetic changes or that these changes were
under genetic control.
In addition to nutritional exposures directly leading to
epigenetic changes that could alter the expression of cancer
susceptibility genes, it is also clear that nutritional exposures
may affect the general systemic metabolic status and hence
the hormonal milieu. These hormonal changes may then
affect cancer susceptibility or progression by changing the
soil within which the cancers develop. It has therefore be-
come clear that much of the heritable component of these
common epithelial cancers identified by classical epidemi-
ology approaches may indeed not be because of the directly
inherited genes but may actually be because of environmen-
tal exposures acting via epigenetic pathways that may affect
both the seed and the soil across generations of families.
Such interactions also complicate the statistical modelling
of gene-environment interactions since they violate the as-
sumption of independence: with some of the genetic variance
clearly depending on exposures.
13 Environmental exposures
In a seminal paper in 1981 Doll and Peto estimated that 30 %
of cancer deaths were due to smoking and 35 % were due to
diet with a variety of other factors contributing to the re-
mainder [139]. In an update in 1998 Doll reiterated that the
incidence of cancer in middle and old age could in principle
be reduced by 80–90 % [140]. That many cancers are in
principle preventable is implied from the large geographical
variations in their incidence. Cancers that are very common
in Western societies are relatively very rare in other regions
of the world, particularly in Eastern countries [68, 141–144].
These geographical variations cannot be completely
explained by differences in ascertainment and it is also clear
that they cannot be explained by simple genetic differences
since there have been many studies of migrants who have
moved between regions of the world were the rates of these
cancers are very different. Such studies have consistently
observed that cancer rates in migrants soon converge to the
cancer rate of the population in their new locale: the time-
frame of such changes excludes genetic differences and
implicates lifestyle and/or environmental exposures [145].
The incidence of breast cancer in migrants from Italy
recently arriving in Australia was half that of native born
Australians but in Italians who had been resident for more
than 17 years the rate had risen to match that of Australians.
Similarly the rates of colorectal cancers in recent arrivals
from Italy and Greece were less than half that of Australians
but these rates were more than doubled in those migrants
resident for more than 17 years [146]. A study of migrants
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from China, Japan and the Philippines who had settled in
California and Hawaii found that breast cancer rates were
30 % higher in those who came from Urban areas in the East
compared with rural areas and migrants who had been in the
USA for more than 10 years had rates 80 % higher than
recent immigrants [147]. The multiethnic cohort study has
compared rates of breast, prostate and colon cancer between
Japanese and Hawaiian Caucasians and Japanese migrants to
Hawaii: the rates of all of these epithelial cancers were
considerably lower in the Japanese but increased in first
and second generation migrants to Hawaii and indeed for
colon cancer had already reached that of Caucasians by the
first generation [148]. A review of prostate cancer in Japan
and the USA found that incidence rates in Japan and other
Asian regions were much lower than that in the USA but
rates in migrants to the US from each of these regions were
considerably higher than that of their homeland [149]. The
incidence of colon, rectal, prostate and breast cancer in China
are also considerably lower than that in the USA but the
incidence in Chinese-Americans approach that of Americans
[143]. The diets traditionally consumed in China and Japan
were very different from that in the USA: in the mid-1950s,
the per capita consumption of red meat in the USA was
254 g/day compared with 28 g/day in China and 14 g/day
in Japan; also, milk consumed in the USA was 530–
670 g/day compared with only 6 g/day in China and
25 g/day in Japan. By contrast, the majority of calories in
the diets in China and Japan were from cereals and grains
with more than double the intake compared with the USA
[143, 144]. Although restricted calorie intake is associated
with lower cancer (as discussed below), the geographical
differences are more complicated than simple differences in
calorie intake. A comprehensive study of diet and lifestyle in
6,500 adults in 130 villages across rural China found that the
calorie intake for the average Chinese man was about 30 %
higher when compared with an average American man of the
same weight [150]. The Chinese men were however much
leaner with a diet low in animal fat and protein but high in
fibre and rich in plant-based foods. The low BMI in the
Chinese men (around 25 % lower than American men) was
mainly attributable to high energy-expenditure and much
greater physical activity. The geographical lifestyle differ-
ences therefore probably relate to overall differences in en-
ergy balance and composition of diet rather than to simple
calorie intake differences.
Similar implications can be learned from countries where
lifestyles have been rapidly changing: Japan was virtually
closed toWestern influences until the 1950s since when there
has been a remarkable Westernisation of dietary habits [151].
This change in exposure has been accompanied by a rapid
increase in the height of Japanese girls followed, with a 30-
year lag period, by a parallel increase in incidence of breast
cancer [152]. This implies that changing environmental
exposures that resulted in increased childhood growth may
also have influenced the subsequent risk of this cancer. A
similar rise in the incidence of prostate cancer throughout
Asian countries has been observed and associated with the
gradual Westernisation of those countries [153]. If the effect
of environmental exposures was on cancer initiation, then
the rates of latent cancers would be expected to increase in
migrants who move from regions of the world with low
incidence of cancers to regions with high incidence. The
available data however indicate that the prevalence of latent
prostate cancers were similar in Japanese migrants to Hawaii
compared with indigenous Japanese [154] despite the in-
crease in clinical cancers. The large changes throughout
society in Japan have been accompanied by a modest in-
crease in the prevalence of latent prostate cancers; the age
adjusted rate was estimated as 22.5 % from an autopsy series
between 1965 and 1979 and had increased to 34.6 % from a
similar series between 1982 and 1986 [155]. This was then
comparable to the rate of 34.6 % in white men in the USA
[156] despite the incidence of clinical prostate cancers being
vastly different at around 10-fold higher in the USA than in
Japan [149]. Together these observations imply that environ-
mental exposures may have a relatively small effect on the
initiation of latent cancers but a large effect on the progres-
sion of cancers to clinical disease.
With exposures that are still prevalent in some Eastern
societies the epithelial cancers are relatively very rare, as are
obesity and diabetes: indicating that metabolic homeostasis
is maintained (Fig. 5a). In those individuals surviving into
old age, such as in Japan, the initiating mutations still accrue
and the occult neoplasias occur but these do not progess to
clinical disease. With the metabolic pertubations associated
with a Western lifestyle however these progress and become
clinically evident (Fig. 5b). In developed societies, the con-
trol of previously life-shortening conditions has also shifted
demographics with many more individuals surviving into
old age. In the rapidly expanding older generations there is
then longer time and a more fertile soil for the prevalent
occult neoplasias to progress to clinical cancers and the tip of
the iceberg becomes even more exposed (Fig. 5c).
With the identification of highly penetrant genes that
conferred an extremely high risk of specific cancers, it was
generally considered that in such cases the contribution of
genetic susceptibility would make environmental influences
of little importance. Evidence has emerged however indicat-
ing that environmental exposures may still have a dominant
role even when there is a clearly identified strong heritable
risk, such as with BRCA1/2 mutations that are thought to
promote genomic instability. Within a community of over
1,000 Ashkenazi Jewish women with inherited mutations in
BRCA1/2, the risk of developing clinical breast cancer by
the age of 50 was 24 % in those born before 1940 but
increased to 67 % in those born after 1940, with physical
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exercise and obesity being factors determining cancer onset
[157]. Similarly for women in Iceland with BRCA2 muta-
tions the risk of developing breast cancer by the age of 70
was 18.6 % in 1920 and had risen to 71.9 % by 2002; over
the same time period in the general population the increased
risk was from 1.8 to 7.5 % [158]. The relative temporal
increase in cancer risk because of environmental changes
was therefore approximately the same in women with a
clearly identified heritable risk as it was for women with
sporadic cancers. The risk associated with BRCA mutations
is so high that women are now recommended prophylactic
total mastectomy, but a century ago the risk in women with
the same mutations would have been approximately equiva-
lent to that of women in the general population of North
America and Western Europe today. Recent studies of
French-Canadian families with inherited BRCA1/2 muta-
tions have examined the aspects of lifestyle associated with
breast cancer risk and found that total energy intake and
weight gain since the age of 18 were positively associated
with risk [159] and dietary vegetable and fruit diversity were
negatively associated [160]. These studies indicate that ex-
posures that determine progression to clinical disease can
have a large effect and operate independently of the initiating
factors.
As the evidence indicates that exposures affect the pro-
gression of common epithelial cancers, an important second-
ary question is when such exposures are having this effect.
This is important if interventions are to be designed to impact
on the course of these diseases. The question is confounded
by the believed, but uncertain, long time frame between
initiation and the clinical presentation of these cancers that
may occur decades later. Direct information is scarce but
there is evidence related to a number of surrogate markers
of exposure. There has been considerable interest in expo-
sures during critical developmental periods early in life in
relation to other chronic disorders in adults, principally met-
abolic and cardiovascular disorders. The Developmental Or-
igins of Adult Health and Disease hypothesis proposes that
foetal nutrition and other exposures result in adaptations of
placental and foetal hormones and that when this occurred
during critical periods during gestation this could result in
the reprogramming of key metabolic hormones such as in-
sulin, IGFs and growth hormone with long-term conse-
quences on metabolic and cardiovascular health in later adult
life [161, 162]. That the risk of cancer may be affected by
early exposures is suggested by the associations observed




Fig. 5 a A pre-industrialisation lifestyle, that is still prevalent in some
Eastern societies, is associated with limited nutritional intake and high-
energy expenditure. Metabolism is then maintained in balance as ap-
parent by the low rates of metabolic disorders, such as obesity and
diabetes, in such societies. With aging, oncogenic mutations naturally
accrue in rapidly dividing epithelial tissues and as a consequence occult
cancers appear; but with metabolism in balance the ‘soil’ is not fertile
and the ‘seeds’ are not stimulated by endocrine signals and do not
progress to clinical disease. The latent oncogenic potential still accu-
mulates with aging but like the bulk of an iceberg it remains submerged.
b The adoption of a Westernised lifestyle with excess nutritional intake
and a sedentary lifestyle results in energy-imbalance perturbing meta-
bolic control as reflected by the increasing prevalence of obesity and
diabetes. This alters the internal ecosystem within the body such that the
naturally occurring occult cancers are given signals to progress, that
together with a more fertile ‘soil’, results in more of them developing to
clinical cancers. cWhen the adoption of a Western lifestyle is combined
with the control of life-shortening conditions then there is a shift in
demographics with more of the population living longer into old age.
This has exacerbated the prevalence of clinical cancers as the occult
cancers, exposed to perturbed metabolic signals, have even longer to
progress to clinical disease. The large burden of oncogenic potential that
naturally accumulates with age then emerges as an epidemic of epithelial
cancers: as the tip of this ‘iceberg’ becomes even more exposed

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childhood growth and height. Birthweight or size, which are
proxys for in utero growth and prenatal exposures, have been
found to be positively associated with the subsequent risk of
breast [163], prostate [164] and colorectal [165] cancers.
Adult height, which is determined by childhood growth
and the tempo of sexual development and is a proxy for
childhood exposures has also been positively associated with
these three common epithelial cancers [166]. Studies of
breast cancer have established that both birthweight and
childhood growth have positive associations with risk
[167] with probable independent effects [168]. The larg-
est study of a cohort of 117,415 women found that the
pubertal growth spurt had a particularly strong effect
and after adjusting for age at peak growth, the age at
menarche was no longer related, despite the wide belief
that this is a strong determinant of breast cancer risk
[169]. These studies could indicate that early exposures
are affecting the tissues or cells predisposing to subse-
quent cancer development or they could indicate that
the early exposures are affecting the soil in which the
subsequent cancers develop.
There is accumulating evidence that nutritional exposures
in early life result in the resetting of hormonal systems with a
programming effect on hormonal levels throughout the rest
of life. A long-term follow-up of a randomised trial of milk
supplementation given during pregnancy and throughout
infancy up to the age of 5 years found that serum IGF-I
levels measured in the subjects 20 years after the end of the
supplementation were reduced compared with subjects not
receiving the additional milk [170]. Milk consumption dur-
ing childhood is positively associated with IGF-I levels [171]
and therefore the long term programming effect is opposite
to the acute effect. Evidence of an even more long-term
effect was obtained in a follow-up of a cohort studied in
the 1930s, subjects from families with high milk consump-
tion in the 1930s (who were then children with an average
age 6.5 years) had lower circulating IGF-I levels when mea-
sured in blood samples taken 65 years later [172]. Further
evidence linking nutrition in early life with IGF-I levels mea-
sured much later in adulthood was obtained in a long-term
follow-up of people exposed to the 1944–1945 Dutch Famine.
This again provided evidence for a paradoxical enduring effect
opposite to the well known short-term effect of reduced nutri-
tion with girls who were seriously deprived of food for almost
6 months at a median age of 12 years having higher levels of
serum IGF-I when measured 51 years later [173]. In a follow-
up study examining breast cancer in women exposed to the
Dutch Famine, a 48 % increased risk was found in women
severely exposed and a 13 % increase in women moderately
exposed: the greatest risk (101 % increased) was observed in
the women who were severely exposed between the ages of 2
to 9 years [174]. Together, these studies indicated that nutri-
tional deprivation in childhood resulted in reprogramming of
systemic hormones with higher adult levels of IGF-I and also
increased the risk of breast cancer decades later.
It appears that for most of the common epithelial cancers,
decades may elapse between initiation and clinical presenta-
tion [4] and it is likely that the effect of perturbed metabo-
lism, consequent to a Western lifestyle, is manifest through-
out but with an amplifying impact in the latter more acceler-
ated stages (Fig. 2). This may be analogous to cardiovascular
disease where the initiation of atherosclerotic plaques can be
detected in autopsies of subjects in their 20s but the clinical
consequences of lifestyle exposures only become evident
decades later.
14 Evidence from intermediate biomarkers of metabolic
exposure
Further evidence that metabolic status may influence cancer
has come from population studies examining associations
between circulating measures of metabolic biomarkers and
the risk of subsequently developing cancers. The circulating
levels of IGF-I have proven particularly attractive for such
studies because these levels are determined by nutritional
and metabolic status and hence could represent a modifiable
risk factor. The circulating levels are also relatively stable
throughout the day and can therefore be measured in untimed
blood samples that may be available in many epidemiology
studies. In addition, the levels of IGF-I within individuals
seem to track over a number of years and therefore reflect
long-term exposures. This enables prospective epidemiology
where inter-individual variation in IGF-I levels can be used
as a measure of exposure and related to subsequent out-
comes, such as the risk of cancer or the risk of progression.
There are also measures of serum insulin but as circulating
insulin levels fluctuate rapidly throughout the day inter-
individual variations are best examined in timed, fasting
blood samples which are not so readily available from pop-
ulation studies; to overcome this some studies have mea-
sured serum levels of C-peptide as a more chronic measure
of insulin secretion. For IGF-I, although there has been some
heterogeneity with findings, there have been a considerable
number of large studies with reasonably consistent findings.
There are many reasons why there have been heterogeneity
of findings: there are a number of analytical pitfalls with
measuring IGF concentrations that can lead to problems for
those inexperienced with these assays. There has also been
considerable heterogeneity in study design with some pro-
spective studies examining associations between IGF-I and
subsequent cancer risk and others being cohort studies where
associations may reflect the host response to cancer. Theo-
retically, associations found in cohort studies could be con-
founded if serum IGF-I levels were affected by IGF-I being
produced in the tumour itself, but this would be extremely
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unlikely due to the known dynamics of the systemic IGF-
system and the evidence in humans confirms that this is
generally not the case. There are also issues of phenotype
heterogeneity with studies examining cohorts suffering from
prostate or breast cancer but individuals within these cohorts
having very different forms of cancer.
Despite their attractions, the interpretation of circulating
IGF concentrations is far from straightforward as the rela-
tionship between serum concentration and tissue production
or tissue bioactivity is far from simple. There are no intra-
cellular stores of IGF-I in the body and the very high serum
concentration appears to primarily represent a circulating
store, maintained by high affinity binding proteins that con-
siderably slow clearance. There is then a complex interplay
between various factors that determines the availability of
IGF-I from this store and its activity in tissues with local
tissue production confounding interpretation further [175].
Despite all of these limitations, robust associations have been
observed between circulating IGF-I concentration and the
three common epithelial cancers. For breast cancer, positive
associations between circulating IGF-I and risk of cancer
have been reported in meta-analyses, systematic reviews
and in a large pooled analysis of 17 prospective studies
[176, 177]. For prostate cancer similar associations have also
been found in meta-analyses, systematic reviews and a
pooled analysis of 12 prospective studies [178, 179]. A
number of studies have also reported positive associations
between circulating IGF-I levels and the risk of colorectal
cancer and these findings also appear to be relatively robust
as indicated in a recent meta-analysis [180].
There is also evidence from population studies of prostate
cancer that suggest that the association with circulating IGF-I
is not because of an effect on cancer initiation but reflects an
effect on the risk of progression to clinically relevant disease.
In a meta-analysis that stratified all published studies
according to those conducted within PSA-screened popula-
tions (the vast majority of cancers that are PSA-screen de-
tected are occult latent cancers) and those studies that in-
volved routine clinically presenting cases: the association
with IGF-I remained for the clinically detected cancers but
no association with IGF-I was observed in the PSA-screened
populations [181]. A large prospective study of nearly 3,000
PSA-detected prostate cancers also found no evidence of an
association between risk of cancer and IGF-I [181]. However,
in 909 of these cases who were then assigned to active
monitoring, there was evidence of an association with bio-
chemical progression as assessed by PSA doubling times after
a mean of 4 years follow-up [182]. In a study of 396 men with
advanced prostate cancers, there was an even stronger associ-
ation between IGF-I and prostate cancer-specific mortality
[183]. If IGF-I is a marker of nutritional/metabolic status then
the lack of association of IGF-I with PSA-detected cancers,
the majority of which are indolent, is consistent with the
autopsy studies that indicate that lifestyle exposures have
relatively little effect on the prevalence of occult cancers.
The associations of IGF-I with progression and mortality
however are consistent with the population studies that indi-
cate that such exposures have a large effect on the progression
to clinical disease.
Reasonably consistent associations have also been found
for more direct measures of metabolic status such as glucose
and insulin levels. There have been some reports of moderate
associations between circulating levels of C-peptide and the
incidence of breast cancer [184, 185]. Although many stud-
ies have not found such an association but a stronger asso-
ciation has been reported with breast cancer mortality [186]
that would be consistent with an effect on disease progres-
sion. For prostate cancer, associations have been reported
between C-peptide and the risk of high-grade cancers [187]
and prostate cancer mortality [188] again supporting a role in
cancer progression. With colorectal cancer there have been
several reports that higher C-peptide confer a greater risk of
adenoma [189–191] implying a possible role in early adeno-
ma formation. Associations between IGF-I and the appear-
ance of adenomatous polyps [192] and between IGF-I and
fasting serum insulin levels and the presence and advance-
ment of adenomatous polyps [193] again support a role for
metabolism in the early development and advancement of
these precancerous lesions.
Although the many studies examining these individual
markers provide accumulating evidence: an even stronger
picture is obtained from a holistic approach considering all of
the evidence together; for example for colorectal cancer there
is evidence from cell biology; animal models; clinical evi-
dence such as the association between acromegaly (which is
characterised by high IGF-I levels) and colorectal cancer
[194]; the blood biomarker associations described above;
epidemiology relating height, body mass index and physical
activity; associations with metabolic disorders such as dia-
betes and obesity and a factorial analysis of dietary intake
associating a Western diet with colon cancer [195]. When all
of this evidence is considered together, the story becomes
even more compelling linking lifestyle, metabolism and the
risk of these epithelial cancers [196]. This raises the feasibil-
ity that a better understanding could lead to lifestyle modifi-
cations that would render these cancers rare in populations
just as they were in societies before industrialisation and
Westernisation.
15 Co-morbidity associations
The major change in energy balance consequent to the adop-
tion of a Western lifestyle has resulted in epidemics of
metabolic disorders especially obesity and diabetes. It has
also been recognised for many years that the geographical
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variations in the common epithelial cancers closely parallels
the spread of these metabolic disorders. The worldwide tally
for those obese is approaching 500 million and rising rapidly.
There is a similar rise in type 2 diabetes: increasing 4-fold
over the last 30 years in the USA. With such large numbers
affected any associated increase in risk of cancers represents
a major public health concern. A prospective study of
900,000 Americans reported a decade ago that increased
body-mass index was significantly associated with higher
rates of death from colorectal, breast, prostate and a number
of other cancers [197]. Since then there have been many
other reports of population studies, meta-analyses and sys-
tematic reviews reporting similar associations with obesity
and recently also increasingly with diabetes. There are many
complications confounding the interpretation of such asso-
ciations in addition to the issues discussed earlier of cancer
heterogeneity and distinguishing between associations with
risk of initiation or disease progression. Obesity itself has
heterogeneous features that may influence cancers con-
founding the effects of the underlying metabolic disturbance;
for example, steroid metabolism is altered, in particular
because of the high expression of aromatase in adipocytes
converting androgens to estrogens. This may contribute little
to estrogen exposure to tissues in premenopausal women but
contribute significantly in postmenopausal women and may
clearly have different effects on prostate cancer in men
compared with breast cancer in women. Associations with
type 2 diabetes may also be confounded by many factors
associated with that condition. Early disease is characterised
by insulin resistance, and epithelial tissues may be exposed
to raised insulin levels but with more advanced diabetes the
pancreas may fail resulting in low insulin exposure but if
systemic insulin therapy is administered then exposure may
again be increased. In population studies different individ-
uals may be on different treatment regimens that may them-
selves affect cancer development and progression in differ-
ent ways. One of the most common drugs used for diabetes is
metformin that, as discussed in the next section, accumulat-
ing evidence indicates may be protective against epithelial
cancers whereas other therapeutic options such as insulin
analogues may not have such an effect. Many of the early
population studies did not discriminate between stage of
diabetes or treatment regimens. In the light of all of these
potential confounding factors, the relatively consistent asso-
ciations reported from population studies are probably
underestimating the true effect of perturbed metabolism it-
self. It is also emerging that associations with cancer pro-
gression are even more robust than those with incident
disease risk. Prognosis and mortality are worse for patients
with diabetes for both colorectal cancer [198] and breast
cancer [199]. In women with breast cancer, a high level of
blood glucose was associated with poor response to chemo-
therapy [200], consistent with in vitro work demonstrating
that hyperglycemia conferred resistance of breast cancer
cells to chemotherapy [201]. In potential contradiction, dia-
betes has consistently been reported to be associated with a
reduced risk of the incidence of prostate cancer [202] al-
though the association appears to be strongest in studies in
the USA [202]. There are a number of potential confounding
issues that may help explain this anomaly, particularly relat-
ing to detection and population screening as several studies
have reported that PSA levels are lower in subjects with
diabetes [203]. In contrast to the effect on incidence however
there are reasonably consistent reports that pre-existing dia-
betes is associated with a poorer prognosis for men with
prostate cancer [204] and for those with diabetes poorer
glycemic control is associated with aggressive cancer
[205]. Considering the high prevalence of these metabolic
disorders in the general population, an increasing number of
patients presenting with cancer have one of these co-
morbidities and this has important implications for progno-
sis, treatment response and survivorship.
16 Progression and metastasis
The accumulating evidence that metabolic disorders may
have a greater effect on prognosis and survival than on
cancer incidence implies that metabolic status may impact
on the processes of progression and metastasis. These infer-
ences have recently been supported by observations that men
who have been treated for prostate cancer who have elevated
blood glucose levels are at 50 % greater risk of disease
recurrence compared with men with normal glucose [206].
Hyperglycemia in women with advanced breast cancer was
found to be associated also with poorer outcome and in-
creased mortality [207]. As metastases are responsible for
around 90 % of all cancer-related deaths [208], the identifi-
cation of modifiable factors that contribute to metastasis
could be extremely important.
The dissemination of tumour cells from the primary site to
establish metastatic lesions at other locations around the
body is a complex multistage process; the understanding of
which has seen major advances over recent years but with
some critical questions remaining unanswered [209, 210].
For a cancer to metastasise, tumour cells need to detach from
the primary site: this involves acquiring increased motility
and an ability to break-down extracellular matrix (ECM).
The detached cells need to enter the circulation via
intravasation into existing or newly formed blood or lymph
vessels. The cells need to survive in the circulation and then
extravasate from the circulation at a secondary site. Here, the
cells encounter a microenvironment that at least initially will
be very different from that in the tumour from which they
departed and the cells need to survive in this new environ-
ment. The cells may just survive here in a relatively dormant
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state for prolonged periods that may last many years but
eventually must resume growth at this secondary site to form
a metastasis or secondary tumour. A number of processes
have been suggested to contribute to these events. A change
in the differentiation status of the epithelial cell referred to as
epithelial mesenchymal transition (EMT) has been heavily
implicated [211]. This involves loss of cell polarity and the
cell-cell adhesion properties characteristic of epithelial cells
and acquisition of increased motility, an ability to invade
through ECM and resistance to the apoptosis normally in-
duced by detachment (anoikis), properties associated with
mesenchymal cells. It has been suggested that EMT may
play a pivotal role in driving carcinomas to a more malignant
stage [212]. The formation of new blood vessels via angio-
genesis has been proposed as not only important for the
supply of oxygen and nutrients to the tumour but also for
providing the tumour cells access to the circulation. The
most enduring concept regarding metastasis has been the
‘seed and soil’ hypothesis originally proposed more than a
century ago [49]: this proposes that metastases only develop
in specific sites where the right context is provided with the
appropriate microenvironment. The concept of an appropri-
ate soil to support a potential metastatic lesion has subse-
quently evolved with an accumulation of evidence
supporting the existence and development of metastatic
niches that provide such an appropriate microenvironment
for the survival and outgrowth of disseminated tumour cells
[213]. Indeed recent evidence has suggested that the soil may
be prepared in advance with the creation of a premetastatic
niche before the first tumour cells actually arrive. Using
experimental models, it has been shown that a distant prima-
ry tumour can induce the mobilisation of bone marrow
derived progenitor cells that cluster in tissues and change
the local environment creating a suitable niche [214]. A
distant tumour in mice has been reported to induce
upregulation of inflammatory chemokines and the recruit-
ment of myeloid cells to promote the formation of a
prematastatic niche [215].
There are clearly many barriers that have to be overcome
for a tumour to spread throughout the body. Individual
adaptations or acquired mutations may not however be re-
quired to overcome each of these barriers. Many normal cells
behave in a similar manner during early development and
even into adulthood with complex patterns of migration
around the body and invasion into tissues. In early develop-
ment, cells migrate from the surface of an embryo to form the
mesoderm during gastrulation, neural crest cells undergo
EMT and invade through tissues as the progenitor cells that
develop into neurons and glia in the peripheral nervous
system and other cells such as melanocytes: similar behav-
iour is also seen in organogenesis [212, 216]. In adults, bone
marrow-derived progenitor cells migrate to peripheral tissues
to form myeloid, endothelial and mesenchymal cells. Many
of the same features, including angiogenesis, are also acti-
vated during wound healing. Similar programs of cell be-
haviour may be inappropriately reactivated in cancer cells
enabling them to acquire a metastatic phenotype [211].
It is clear that the genetic factors that initiate oncogenic
transformation are in themselves generally not sufficient for
the development of metastases as evidenced by the observa-
tions that most mouse subcutaneous xenograft models and
many oncogene-driven mouse models fail to form metastatic
lesions [210, 217]. The implications from the clinical reports
that metabolic disorders may adversely affect progression
and survival have been supported by various experimental
models. In a model of xenografts formed from Lewis lung
cancer cells; when the mice were fed with either a high fat or
a high sugar diet, either of these diets both more than doubled
the rate of metastases [218]. In a orthotopic syngeneic mouse
model of triple negative breast cancer, a high energy diet
promoted tumour growth, induced lung priming by bone
marrow-derived myeloid cells and considerably increased
the number of lung metastases [219]. In an autochthonous
mouse model of prostate cancer, aWestern-type diet was also
shown to increase the number of lung metastases [220].
Several mechanisms have been proposed to explain the
effects of diet and metabolic status on tumour progression
and metastasis. Adipokines released from fat cells are a
potential mediator although studies in fatless mice that have
undetectable levels of adipokines have shown that diabetes
still enhances tumour formation although effects on metas-
tasis have not yet been reported [221]. From the discussions
above, it is clear that the insulin/IGF system are prime
suspects because of their conserved function in integrating
tissue metabolism and growth. In a series of studies in which
two different strategies were used to induce mammary tu-
mours in mice in which different genetic manipulations were
used to render the mice insulin resistant: it was shown that
the insulin resistance consistently increased the number of
lung metastases [222–224]. In a mouse model with
transplanted colorectal tumours, systemic hyperglycemia
was found to increase circulating levels of IGF-I and tumour
expression of vascular endothelial growth factor (VEGF) a
critical mediator of angiogenesis [225]. In most cancers that
have been examined IGF-I has been found to be a potent
regulator of VEGF expression [226]. Inactivation of hepatic
expression of IGF-I, resulting in a 75 % reduction in its
circulating concentration, significantly reduced metastasis
to the liver in an orthotopic model of colon cancer [227]. In
a further study, diet-induced obesity was found to result in an
inflammatory response in the liver in control normal mice
and this was associated with an increased incidence of he-
patic metastasis following direct intrasplenic/portal inocula-
tion of colon carcinoma cells [228]. The effects of obesity on
this inflammatory response in the liver and on the enhanced
efficiency of metastasis were not however seen in mice in
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which hepatic IGF-I expression was negated [228]. This
implied that IGF-I was critical for sustaining an obesity-
induced metastatic niche in the liver. That humoral factors
mediate the effects of obesity is supported by observations
that when prostate cancer cells were exposed to serum taken
from mice with diet-induced obesity an increase in cell
migration, invasion and markers of EMT were observed
relative to cells exposed to serum from control mice [229].
An inflammatory microenvironment may recapitulate the
tumour-stroma interactions in the primary tumour and sup-
port the development of a metastatic niche and in addition it
may modulate EMT [213]. A number of inflammatory me-
diators and cytokines may facilitate metastases by promoting
angiogenesis, cell migration and invasion and inhibiting
apoptosis [230]. This experimental evidence together with
the clinical observations indicates that metastases may be
critically affected by the metabolic context within the body.
These studies confirm that perturbed metabolism is asso-
ciated with enhanced cancer progression and metastasis:
other recent findings indicate that altered cell metabolism
may indeed initiate these events. Induction of the Warburg
metabolic switch in human cancer cells, by genetic silencing
of the respiratory enzyme citrate synthase, resulted in greatly
increased glycolytic metabolism and this was reported to
induce EMT and enhance metastases in an mouse xenograft
model [231]. Reversal of the Warburg effect by silencing of
expression of pyruvate dehydrogenase kinase 1 in breast
cancer cells also restored their sensitivity to anoikis when
detached and reduced lung metastasis by 5-fold when they
were inoculated in a mouse model [232]. It has long been
recognised that developmental EMT can be induced by ex-
posure to hyperglycemia, and it has recently been demon-
strated that exposure to hyperglycemia can similarly induce
EMT of human lung adenocarcinoma cells [233]. Accumu-
lating clinical studies indicate that the experimental evidence
implicating EMT in cancer dissemination and metastasis
may also apply to human cancers [211]. This has recently
been further supported by a study that showed that circulating
breast tumour cells were enriched in cells expressing mesen-
chymal markers whereas mesenchymal markers were only
rarely found in cells from the matched primary tumours [234].
Taken together, these studies indicate that exposure to
adverse metabolic conditions can induce EMT and initiate
the whole program necessary for metastatic progression.
Metastases could be facilitated by processes such as EMT
that drive cancer cells into behaviour patterns that are similar
to that seen in normal cells during early development and
organogenesis. Early development is critically dependent on
adequate supply of nutrients with the conserved insulin/IGF
signalling pathway regulating cell growth, survival and me-
tabolism in an integrated manner by switching on and off a
program of appropriate genes via a family of gene regulators,
the forkhead box O (FOXO) transcription factors [235]
(Fig. 4). There are at least 43 distinct members of the FOXO
family of proteins and several of these have been implicated
in the regulation of EMT [211]. Recent evidence indicates
that breast cancer prognosis is associated with a differential
pattern of estrogen receptor (ER) nuclear binding to genes
that was determined by a reprogramming of ER binding to
these genes by FOXA1 (a FOXO transcription factor); ER
and FOXA1 were also found to be co-expressed in samples
from metastatic lesions obtained from women with advanced
disease [236]. FOXA1 plays a crucial role in developmental
ductal morphogenesis in the breast and it has recently been
demonstrated that it is a critical mediator of IGF-I effects on
breast cancer cell growth and survival [237]. In addition to
enabling gene expression, FOXA1 can also repress genes by
competing with another FOXO protein, FOXA2, and the
pattern of genes activated or repressed is then determined
by the relative levels of FOXA1/FOXA2 and this ratio is
modulated by insulin/IGF signalling [238]. FOXA2 inhibits
EMT [239] and hence FOXA1 by competing with FOXA2
could facilitate EMT. FOXA2 has also been identified as a
critical regulator of colorectal cancer metastasis to the liver
[240]. Another related transcription factor FOXC1 was as-
sociated with the EMT observed in disseminated circulating
breast cancer cells [234] and has been linked to the induction
of EMT in breast cancer cells [241, 242]. FOXC1 has also
been reported to promote the invasiveness of breast cancer
cells by inducing the expression of matrix metalloprotease 7
an enzyme known to be able to degrade components of the
ECM [243].
A key event in EMT is the loss of E-cadherin which
connects neighbouring epithelial cells and hence its loss
enables cell migration and invasion [244]. E-cadherin also
however acts as a negative regulator of the WNT signalling
cascade by controlling the cellular localisation of the critical
mediator β-catenin. β-catenin associates in a complex with
E-cadherin at the cell membrane and the loss of E-cadherin
may permit the translocation of β-catenin to the nucleus
where it can induce the expression of genes that promote
an invasive phenotype. There is considerable cross-talk be-
tween WNT and IGF signalling: IGF-I is induced by, and in
turn activates, WNT signalling in a feed-forward loop [244].
This cross-talk with metabolic regulators may enable the
acceleration of EMT in compromised metabolic conditions
and hence promote metastasis.
Measures of dissemination of tumour cells into the circu-
lation indicate that more than a million cells can be shed
daily per gram of tumour [245]. Experimental models how-
ever also indicate that the efficiency of metastasis is very
low, generally estimated to be less than 0.01 % [4]. The
‘seeds’ appear to be extremely plentiful and the rate limiting
factors are the survival of the seeds in the circulation, their
ability to extravasate into secondary sites and the suitability
of the soil at these sites. With such a low efficiency process,
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any factor that has even a small effect could have a very
important impact on metastasis. The different strands of
emerging evidence indicate that metabolic exposures and
metabolic regulators may promote these metastatic processes
and hence could be important determinants of the progres-
sion of epithelial cancers, and consequently mortality.
An alternative hypothesis for how environmental expo-
sures associated with a Western lifestyle could contribute to
the prevalence and progression of epithelial cancers stems
from the ‘hygiene hypothesis’. A traditional lifestyle, as
experienced throughout most of human evolution, was
characterised by continuous exposure to environmental
microbiota that induced and strengthened the adaptive im-
mune system. This could help prevent the establishment of
chronic tissue inflammation that, as described above, may
contribute to the creation of metastatic niches. A Western
lifestyle, associated with urban living in a microbe-poor
environment may however compromise the development of
the adaptive immune system and hence promote the creation
of metastatic niches [230]. The effects of lack of exposure to
environmental microbes and exposure to a lifestyle that
compromises metabolic controls are not mutually exclusive.
Indeed the considerable cross-talk between metabolic and
inflammatory mediators, as mentioned above, could result in
these exposures having a compounded effect on cancer
progression.
17 Metabolic interventions
Since the realisation that diet may contribute to a large
proportion of common cancers, there have been many inter-
vention studies investigating the role of various dietary fac-
tors that may impact on cancer risk. Although there is con-
vincing evidence linking some dietary components with
specific cancers, there have not been major breakthroughs
to explain the majority of the effects of nutrition on cancer
rates. This is undoubtedly at least partly due to the complex-
ities of diet and the inaccuracies of techniques available to
measure nutrition. Comparisons between countries and in
particular regions of the world with large differences in diet
show clear associations between a number of foods and
cancer rates particularly hormone-dependent cancers [246,
247]. Similar comparisons within individual countries have
however generally failed to replicate such associations; this
may at least partly be due to the relatively small variations in
diet within a country, which are not much greater than the
errors in the methods for measuring diet [248]. The associ-
ations of cancer with some dietary components have been
supported by considerable experimental evidence leading to
large clinical trials with specific nutritional interventions and
these have led to many prominent and very costly disap-
pointments. A trial of the effects of a low fat, high fibre diet
on the recurrence of colorectal adenomas in 1,429 subjects
failed to demonstrate any effect [249] even after 8 years of
follow-up [250]. Even more unsuccessful was supplementa-
tion with folic acid in 1,021 subjects, which increased the
risk of recurrence of multiple or larger colorectal adenomas
[251]. A large trial of β-carotene and vitamin E supplements
to prevent lung cancer in 29,133 men was again unsuccessful
with an outcome indicating that high-dose β-carotene sup-
plementation increased the risk of lung cancer in smokers
[252]. A randomised trial of selenium and vitamin E, alone
or in combination, for the prevention of prostate cancer in
35,533 healthy men across 427 participating centers was
discontinued early due to no evidence of benefit for either
supplement [253].
Despite the failure to find a simple single dietary compo-
nent that can generally reduce cancer, there is still consider-
able evidence that nutrition and metabolic status are of
critical importance for the progression of the common epi-
thelial cancers. Compared with the lack of success with food
supplements in human populations, the most well
established intervention for reducing cancer incidence in
experimental animal models across a range of species is a
general reduction in nutritional intake or calorie restriction
[254]. Several mechanisms have been proposed for the pro-
tective effect, but calorie restriction consistently lowers the
systemic levels of IGF-I and replacing the IGF-I with infu-
sions in calorie restricted mice to prevent any reduction
negated the benefits in terms of reduced tumour promotion
[255, 256]. This implied that the reductions in IGF-I medi-
ated the beneficial effect of dietary restriction. That reduced
nutritional intake and reduced IGF-I activity act via a com-
mon pathway is also supported by the observation that die-
tary restriction fails to inhibit cancers induced by constitutive
activation of signalling pathways downstream of the IGF-I
receptor [257]. Direct evidence that calorie restriction re-
duces cancer in humans is lacking but there is some evidence
that would be consistent with the effect being the same in
humans. In Okinawa, Japan, up until the 1960s the diet was
characterised by chronic low caloric intake relative to Japa-
nese on the mainland with a diet containing approximately
10.9 % fewer calories than required for maintenance of body
weight (according to Western criteria) and mortality rates for
breast and prostate cancers were approximately half that of
mainland Japan and mortality from colon cancer was 38 %
lower in men and 60 % lower in women [258]. This obser-
vational study is consistent with a calorie restricted state
reducing mortality in a Japanese population: a population
where the rates of these cancers are already considerably
lower than that in North America and western Europe.
In addition to nutritional interventions, interest has been
growing in pharmaceutical interventions that target metabol-
ic pathways. Following the many lines of evidence indicat-
ing that the IGFs are important for many cancers, virtually
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every pharmaceutical company invested heavily in develop-
ing drugs targeted at the IGF-I receptor. Despite the compel-
ling preclinical evidence, the many trials for a range of
cancers have largely been very disappointing; although all
trials thus far have been on all patients without any attempt to
select those that may be more responsive. There are several
potential reasons for the failure of trials targeting the IGF-I
receptor [259]: these include constitutive activation of the
PI3K pathway due to the common mutations in PIK2CA or
PTEN which render cells independent of upstream receptor
activation; the absence of the receptor substrate, IRS-1, that
leads to the receptor signalling for differentiation rather than
proliferation or survival; the presence of alternatively spliced
insulin receptors that respond to IGF-II which is frequently
overexpressed due to imprinting defects and the activation of
the ERK pathway due to overexpressed Ras or Raf again
bypassing dependence on IGF-I receptor activation. The
recent demonstration that an IGF binding protein-related
protein IGFBP-rP1 binds directly to the IGF-I receptor and
prevents ligand binding suggests an additional mechanism
with tumours overexpressing this protein also becoming
independent of IGF-I receptor and hence resistant to its
targeting [260]. It is feasible that activation of the pathway
is so essential for tumour progression, since growth will not
occur without a signal indicating that a ‘fed-state’ is present,
that by the time that such interventions are instigated most
tumours have acquired an autonomous way to sustain the
pathway activition.
One of the most effective preventative interventions has
been the long-term use of daily aspirin, which inhibits the
activity of cycloxygenase-2 (COX-2) and reduces prosta-
glandin activity. In a meta-analysis of eight trials the use of
daily aspirin for 7.5 years or longer reduced mortality from
all solid tumours by 31 % and death from gastrointestinal
cancers by 59 % [261]. A recent analysis of regular aspirin
use following diagnosis of colorectal cancer in two large
cohorts reported that cancer-related death was reduced by
82 % in subjects with cancers characterised by mutations in
the PIK3CA gene whereas in the much larger numbers of
subjects with no mutations in PIK3CA there was absolutely
no effect on mortality [262]. The large effect of aspirin on
colorectal cancers has been suggested to be unlikely due to
effects on PIK3CA tumours alone as these only account for
10–20% of such cancers [263], but as discussed earlier, there
are many other potential aberrations in this pathway in can-
cers with which COX-2 inhibitors may interact. These recent
findings suggest that the efficacy of aspirin may depend on
the activity of the PI3K pathway implying an interaction
with metabolic regulation.
More direct evidence of the potential for pharmaceutical
manipulation of metabolic pathways comes from the grow-
ing interest in the use of metformin, one of the most com-
monly used anti-diabetic drugs, for preventing or treating
cancer. Surveillance studies of patients with diabetes have
indicated lower rates of cancer in those treated with metfor-
min [264]. Metformin has several potential mechanisms of
action [265, 266] but one of the most well characterised is via
activation of AMP-activated protein kinase (AMPK) an in-
tracellular signalling enzyme that is normally activated when
the ratio of AMP to ATP in the cell rises. This enzyme is
therefore normally activated when energy stores, and hence
ATP levels, are reduced and AMPK is activated by hormones
such as adiponectin that signals when systemic adipose
tissue stores of energy are depleted. Thus while insulin and
the IGFs are systemic signals that indicate that the organism
is in the ‘fed state’ and nutrients and energy are available to
support growth: the activation of AMPK is the opposing
signal indicating that circumstances are not appropriate to
support growth. An effect of metformin reducing cancer
progression would therefore be entirely consistent with all
of the evidence regarding metabolism and the effects of
insulin and IGFs on cancer progression. Tumours, just like
tissues in early development, may only grow and develop
when signals indicate metabolic conditions are appropriate.
In addition to activating AMPK pharmacologically, a natural
way to reduce ATP levels is via physical activity and exercise
that burn off the energy. There has been a recent surge in
interest in the role that physical activity and exercise may
play as an exposure that could affect cancer progression and
as a potential intervention [267, 268]. AWestern lifestyle is
characterised not only by nutritional excess but also by a
very sedentary lifestyle.
18 Obstacles
To further our understanding of the role of lifestyle and
metabolism in the progression of these epithelial cancers
and realise the potential to reverse the epidemics in Western
societies, there are a number of obstacles that need to be
overcome. The dogma that genetic damage is the rate-
limiting step and that cancer is an intrinsic problem of the
cancer cell has to be overcome. There has to be wider
appreciation that most epithelial cancers in older humans
arise from perfectly normal mutation rates and that most
elderly humans harbour many latent occult tumours: it is
clear that this is just normal aging. It follows that preventing
the initiation of cancer may then actually require a cure for
the aging process itself: an ambitious goal. However, as the
vast majority of these lesions are indolent, the important and
clinically relevant question is what makes these lesions
progress to rapid growth and invasion in a few individuals.
This is the step in carcinogenesis that is potentially modifi-
able. The emphasis should then shift to factors that promote
progression and metastasis: features of the disease that
makes cancer a life-threatening condition. This will require
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somewhat of a departure from the trend for evermore-closer
gene-centric focus on autonomous cell regulation. A broader
approach is needed to gain a more comprehensive under-
standing of the organism as a whole and the context in which
cancer cells develop and progress. Amore holistic approach to
lifestyle, energy balance and diets is also required, rather than
searching for a single dietary component or a magic bullet.
The use of cell culture models has evolved inadvertently
in such a way that the context of these cells is vastly different
from that of cells in solid tumours. Virtually, all cell culture
work is undertaken with cells grown in media that contains
grossly super-physiological levels of glucose with unlimited
supply of oxygen, vitamins, multiple nutrients and either an
excess of growth factors or undefined growth factors present
in serum. None of these exposures even closely resembles
the environment of cancer cells within human solid tumours
and the metabolic status of the cells used in most laboratory
studies will be nothing like that of cells in real tumours. We
have shown that the response to chemotherapy agents of
breast cancer cells cultured in euglycaemic conditions can be
considerably different to that when the cells are grown in their
conventional media that is very hyperglycaemic [201]. More
work needs to be done with cells grown in conditions relevant
to real human cancers in order to understand how their met-
abolic status affects their behaviour and response to therapies.
The use of appropriate animal models has to be re-
evaluated which will require overcoming a number of
dogmas that have spread through the research community
regarding the importance of current models. Human cancers
develop due to interactions between cancer cells and the host
tissue. Context is critical (as described above): within tu-
mours there is considerable genetic and epigenetic heteroge-
neity and the host tissues reside within human populations
that constitute billions of different genotypes each adapted
and modified by lifestyle and exposures. In stark contrast,
the standard mouse model is a mouse strain that is genetical-
ly entirely homogeneous, every mouse is genetically identi-
cal, and the animals live a sedentary life with continuous
access to food, within confined containers in standardised
conditions with constant day-night cycles and hence no
environmental stimuli. As a result, these animals are very
inactive, relatively overweight, insulin resistant and live
much shorter lives than ‘normal’ rodents living in their
natural habitats that are considerably more active and feed
intermittently [269]. The standard mouse model therefore
examines the interaction between homogeneous cancer cells
inoculated or transplanted into homogeneous mice that are in
a single, very artificial, metabolic state. This is a very poor
model of the infinitely variable genetic and phenotypic in-
teractions that contribute to the development of human can-
cers [217]. The majority of human epithelial cancers are
chronic diseases with estimates of between 12 and 25 years
intervening between initiation and diagnosis [4]; in contrast
most mouse models are initiated by the introduction of
millions of cancer cells and have rapidly developing tumours
with interventions started soon after tumour initiation. Inter-
vening in a newly formed tumour may bare no relation to
intervening in a tumour that has developed and evolved over
decades. All of these factors are pragmatic, to expedite quick
results, but all differ considerably from human cancers.
That mouse models are poor models of complex human
diseases has been confirmed recently in a very comprehensive
evaluation of the genomic response to inflammatory condi-
tions: the genomic response in humans was very similar for
inflammatory responses of different etiologies but the various
mouse models correlated poorly with the human conditions
and poorly with each other [270]. Indeed the conclusion from
this large collaborative study was that the mouse models
ability to mimic human inflammatory diseases was close to
random. The problems encountered in getting that substantive
work published illustrates the kind of barriers that have to be
overcome when challenging ingrained dogmas. Like inflam-
matory diseases, human cancers are similarly complex dis-
eases and yet most interventions are still initially validated in
mouse models in which the mice are all of one single genotype
(and often lacking an immune system). Humans die when
their cancers metastasise whereas the drugs are tested against
mouse xenograph tumours that very rarely metastasise. New
drugs are tested in these models as mono-therapy or at most
dual therapies whereas in humans most phase 3 trials normally
involve the standard chemotherapy regimen with or without
the new drug. An analysis of 213 phase 1 clinical trials
between 1991 and 2001 involving 6,474 cancer patients found
the overall objective clinical response rate was just 3.8 % with
a toxic death rate of 0.54 % [271]. Almost all of the drugs
tested would have been initially validated in mouse subcuta-
neous xenograft models, and if these combined trials were
viewed as an experiment to ask whether these models mim-
icked the response in humans then, with 96.2 % of humans
failing to respond as in the mouse models, the conclusion
would clearly be negative. Recently, much better mouse
models have been developed with more orthotopic cancer
models and transgenic models in which genes can be switched
on or off to initiate endogenous tumours in mice with intact
immune systems; but there is still a lack of evidence that these
new models will better predict the response of human cancers
[217]. Most genetically engineered mouse models result in
rapidly developing tumours with one single genotype in mice
that are also genetically homogeneous: such models test the
interaction of a single cancer genome with a single host
genome. It is now clear that human tumours are extremely
heterogeneous even within an individual and these tumours
occur in individuals with infinitely variable genotypes and
extrapolating findings from the genetically engineered mice
can only give a very limited picture of the complexity of the
human disease. A better understanding of the human disease
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will require a shift from model systems to more translational
clinical research.
The variability, lack of rigour and lack of reproducibility
of preclinical cancer research was highlighted by a recent
report from the oncology laboratory of a prominent biotech-
nology firm where they tried to reproduce the findings from
53 landmark publications and found that the findings of only
6 of these studies could be confirmed [272].
If dietary and lifestyle exposures contribute considerably
to the progression of many epithelial cancers then a better
understanding could lead to more effective prevention and
treatments. There will then undoubtedly be obstacles in
terms of acceptability and compliance: it is likely that severe
calorie restriction may work—but it would not be very
acceptable to many and difficult to attain good compliance
as a public health measure. Our first priority must however
be to provide the evidence and then people will at least have
the choice of whether to act on that evidence.
19 Summary: the soil and the systemic milieu
Mutations to oncogenes and tumour suppressor genes occur
in millions of cells in all of us throughout our lifespan. The
accumulation of these mutations are undoubtedly essential to
cancer initiation, however they do not appear to be sufficient
for the clinical progresson of most epithelial cancers. Muta-
tions occur very frequently and even mutations in oncogenes
and tumour suppressor genes very rarely ever result in the
initiation of a neoplastic growth and very few of these
neoplastic lesions ever progresses to form a tumour of clin-
ical significance. Although the seeds are plentiful, it is clear
that they only germinate if the soil is right: the internal milieu
is set not only by local tissue architecture but also by the
availability of metabolic substrates and the levels of hor-
mones, growth factors and cytokines that regulate these.
Metabolic control is not just a hallmark of cancer it is even
more fundamental, it is an axiom of life itself: every biolog-
ical function is dependent on the availability of the necessary
substrates and the generation of energy and therefore metab-
olism has to be regulated accordingly. Cells must change
behaviour to form a tumour; most of the changes involved
could just be due to inappropriate activation of programs that
are normally only active in early development or during
wound healing. The necessary resetting of cell metabolism
may be a direct consequence of this reactivated program. The
autonomous cell metabolism controls that evolved in single
cells have however been superceded in complex metazoans
by systemic regulators that ensure that all tissue functions are
synchronised to the metabolic status of the organism as a
community of cells. While malignant cells are in many ways
antisocial and no longer work for the good of the general cell
community, the accumulating evidence indicates that
systemic metabolic conditions still greatly influence the abil-
ity of neoplastic epithelial cells to transform and adopt a
malignant phenotype [273].
As we age, the genetic damage accumulates but the soil
also changes. Age is the strongest risk factor for the common
epithelial cancers and although many of these cancers are
dependent on sex steroids they most commonly occur at a
time in the lifespan when the levels of sex steroids are
declining. As described above, IGF-I is heavily implicated
for also playing an important role in these common epithelial
cancers, but the levels of IGF-I also decline with age and are
relatively low at the age when these cancers commonly
occur. When rhabdomyosarcoma cells were inoculated into
rats of different ages the number of resulting lung tumours
was greatest in the youngest rats and correlated positively
with the IGF-I-activity in the lung [274]. Some clinical
evidence that age-related changes in the internal milieu affects
tumour growth have also been reported; for example, the local
recurrence of breast cancer in a long-term follow-up after
partial mastectomy was found to be considerably higher in
women younger than 46 years compared with women older
than 65 and women younger than 35 had an increased risk of
distant metastases [275]. It is possible that the age-related
decline in levels of hormones may confer some protection
against the development of cancers due to the inevitable
accumulating genetic damage. This protection against cancer
afforded by a soil that becomes increasingly less fertile for
tumour development may be dependent on age-related
changes in hormones but these hormones are also heavily
influenced by lifestyle. Our current lifestyles are characterised
by high-energy intake and low energy-expenditure working
together to create a large energy imbalance. Our sedentary
living patterns are exacerbated by a combination of automated
transport and increasingly desk-based work and television/
online recreational activities. These decreases in energy-
expenditure have occurred at the same time as dramatic
changes in nutrition with diets comprised of mainly energy-
dense processed foods. Our current lifestyles entail an energy-
imbalance that would have been extremely rare throughout the
many millenniums of evolution up until the very last few
decades and hence the design has not evolved to adapt to such
conditions and the consequences of such a metabolic imbal-
ance are clearly evident from the epidemics of obesity and
diabetes. This metabolic imbalance has however also dramat-
ically altered the soil in which many latent occult cancers
naturally accumulate as we age (Fig. 5).
20 Conclusions
In combination, these different lines of evidence not only
indicate the importance of metabolism for the common epi-
thelial cancers and the major role played by lifestyle and
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environmental exposures, but they also importantly suggest
that most cancers are in principle avoidable even when there
is a high genetic susceptibility. The seeds for cancers are
plentiful and accumulate naturally with aging; they however
need the right soil and the soil needs to be fertile and this is
strongly influenced by lifestyle. With a better understanding
of the lifestyle and environmental exposures that influence
risk and progression, effective prevention should therefore
be feasible. The scale of potential benefit can be assessed by
the protection from the cancers that are common in
Westernised countries that was afforded by the Japanese
lifestyle as in the 1950s: that the protection was due to
lifestyle and not genes has been confirmed by many studies
including evidence from the rapid changes in Japan over the
following years and also evidence from studies of migrants.
When compared with the USA mortality from breast cancer
was 92 % lower, from prostate cancer 86 % lower and from
colorectal cancer 78 % lower in men and 81 % lower in
women [144]. With such a large potential to reduce the
burden of cancer throughout the developed world, it is re-
markable that research in this area has received relatively so
little emphasis. The re-emergence, or re-discovery, of me-
tabolism as a central issue in cancer research could take us
further to realising this potential.
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